<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Levendag, P.C.</title>
    <link>http://repub.eur.nl/res/aut/1063/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Intensity-modulated radiotherapy followed by a brachytherapy boost for oropharyngeal cancer (Article)</title>
      <link>http://repub.eur.nl/res/pub/39470/</link>
      <pubDate>2013-03-19T00:00:00Z</pubDate>
      <description>Background: The purpose of this study was to reduce the incidence of radiation-induced toxicity in patients with early-stage oropharyngeal cancer, using highly conformal radiation techniques. Methods: Between 2000 and 2011, 167 patients with T1-3N0-3 oropharyngeal cancer were treated with 46-Gy intensity-modulated radiation therapy (IMRT) followed by 22-Gy brachytherapy boost. In patients with node-positive disease, neck dissection was performed. Results: The 5-year Kaplan-Meier estimates of local control, regional control, disease-free survival (DFS), and overall survival (OS) were 94%, 97%, 84%, and 72%, respectively. Feeding tubes were required in 26% of the patients. Grade ≥2 late xerostomia and dysphagia were 11% and 8%, respectively. Chemotherapy, tumor subsite, and bilateral neck irradiation correlate significantly with toxicity. Quality of life (QOL) scores deteriorate during and shortly after treatment but returned in all scales to baseline scores within 6 to 12 months, with the exception of xerostomia. Conclusion: Brachytherapy boost and neck dissection (in node-positive oropharyngeal cancer) after 46-Gy of IMRT resulted in excellent outcomes with low incidence of late toxicity and good QOL scores. </description>
    </item> <item>
      <title>Temoporfin mediated photodynamic therapy in patients with local persistent and recurrent nasopharyngeal carcinoma after curative radiotherapy: A feasibility study (Article)</title>
      <link>http://repub.eur.nl/res/pub/37760/</link>
      <pubDate>2012-09-01T00:00:00Z</pubDate>
      <description>Background: The treatment of persistent and recurrent nasopharyngeal carcinoma (NPC) remains a challenge, especially in Indonesia. We investigated the safety and efficacy of temoporfin mediated photodynamic therapy (PDT) for patients with local persistent and recurrent NPC. Material and methods: Twenty-two patients with persistent and recurrent NPC (maximum tumor depth &lt;10mm) underwent PDT under local anesthesia with use of a nasopharyngeal light applicator. Three different drug doses and light intervals have been administered: treatment arm A: 0.15mg/kg Foscan®; 96h drug-light interval; B: drug dose of 0.10mg/, 48h drug-light interval; C: drug dose of 0.075mg/kg, 24h drug-light interval. Toxicity was measured by using the CTCAE 3.1 scale. Results: Arm A consisted of eight patients, arms B and C consisted of seven patients. The treatment procedure was well tolerable under local anesthesia. The most common grade III toxicities for all groups is headache (n=7; 33%). No grade IV toxicity was seen. One patient died 2 days after treatment due to a misdiagnosed pneumonia. In 17 of the 22 patients a biopsy was performed after 40 weeks and showed no tumor in all biopsies. Arm A seems, in addition to comparable toxicity, clinically more effective than arms B and C. Conclusion: The present study demonstrated that temoporfin mediated photodynamic therapy is a relatively simple technique that can be utilized to treat residual or recurrent nasopharyngeal cancer, restricted locally to the nasopharynx. </description>
    </item> <item>
      <title>Single vocal cord irradiation: A competitive treatment strategy in early glottic cancer (Article)</title>
      <link>http://repub.eur.nl/res/pub/33580/</link>
      <pubDate>2011-12-01T00:00:00Z</pubDate>
      <description>Introduction: The treatment of choice for early glottic cancer is still being debated; ultimately it relies on the functional outcome. This paper reports on a novel sparing 4D conformal technique for single vocal cord irradiation (SVCI). Material and methods: The records of 164 T1a patients with SCC of the vocal cord, irradiated in the Erasmus MC between 2000 and 2008, were analyzed for local control and overall survival. The quality of life was determined by EORTC H&amp;N35 questionnaires. Also the VHI (voice handicap index), and the TSH (thyroid stimulating hormone) blood levels, were established. On-line image guided SVCI, using cone beam CT or stereotactic radiation therapy (SRT) techniques, were developed. Results: A LC rate at five-years of 93% and a VHI of 12.7 (0-63) was determined. It appeared feasible to irradiate one vocal cord within 1-2 mm accuracy. This way sparing of the contralateral (CL) vocal cord and CL normal tissues, could be achieved. Conclusions: Given the accuracy (1-2 mm) and small volume disease (CTV limited to one vocal cord), for the use of stereotactic RT techniques SVCI with large fraction sizes is currently being investigated in clinic. It is argued that hypofractionated SVCI can be a competitive alternative to laser surgery. </description>
    </item> <item>
      <title>Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: Long-term results of the dutch randomized dose-escalation trial (CKTO 96-10 Trial) (Article)</title>
      <link>http://repub.eur.nl/res/pub/33882/</link>
      <pubDate>2011-03-15T00:00:00Z</pubDate>
      <description>Purpose: To assess the impact of dose escalation of radiotherapy on quality of life (QoL) in prostate cancer patients. Patients and Methods: Three hundred prostate cancer patients participating in the Dutch randomized trial (CKTO 69-10) comparing 68 Gy with 78 Gy were the subject of this analysis. These patients filled out the SF-36 QoL questionnaire before radiotherapy (baseline) and 6, 12, 24, and 36 months thereafter. Changes in QoL over time of ≥10 points were considered clinically relevant. Repeated-measures regression analyses were applied to estimate and test the QoL changes over time, the differences between the two arms, and for association with a number of covariates. Results: At 3-year follow-up, the summary score physical health was 73.2 for the 68-Gy arm vs. 71.6 for the 78-Gy arm (p = 0.81), and the summary score mental health was 76.7 for the 68-Gy arm vs. 76.1 for the 78-Gy arm (p = 0.97). Statistically significant (p &lt; 0.01) deterioration in QoL scores over time was registered in both arms in six scales. The deterioration over time was more pronounced in the high-dose arm for most scales. However, clinically relevant deterioration (&gt;10 points) was seen for only two scales. None of the tested covariates were significantly correlated with QoL scores. Conclusion: Dose escalation did not result in significant deterioration of QoL in prostate cancer patients. In both randomization arms, statistically significant decreases in QoL scores over time were seen in six scales. The deterioration of QoL was more pronounced in the physical than in the mental health domain and in some scales more in the high- than in the low-dose arm, but the differences between arms were not statistically significant. Copyright </description>
    </item> <item>
      <title>Does atlas-based autosegmentation of neck levels require subsequent manual contour editing to avoid risk of severe target underdosage? A dosimetric analysis (Article)</title>
      <link>http://repub.eur.nl/res/pub/23962/</link>
      <pubDate>2011-03-01T00:00:00Z</pubDate>
      <description>Background and purpose: To investigate the dosimetric impact of not editing auto-contours of the elective neck and organs at risk (OAR), generated with atlas-based autosegmentation (ABAS) (Elekta software) for head and neck cancer patients. Materials and methods: For nine patients ABAS auto-contours and auto-contours edited by two observers were available. Based on the non-edited auto-contours clinically acceptable IMRT plans were constructed (designated 'ABAS plans'). These plans were then evaluated for the two edited structure sets, by quantifying the percentage of the neck-PTV receiving more than 95% of the prescribed dose (V95) and the near-minimum dose (D99) in the neck PTV. Dice coefficients and mean contour distances were calculated to quantify the similarity of ABAS auto-contours with the structure sets edited by observer 1 and observer 2. To study the dosimetric importance of editing OAR auto-contours a new IMRT plan was generated for each patient-observer combination, based on the observer's edited CTV and the non-edited salivary gland auto-contours. For each plan mean doses for the non-edited glands were compared with doses for the same glands edited by the observer. Results: For both observers, edited neck CTVs were larger than ABAS auto-contours (p ≤ 0.04), by a mean of 8.7%. When evaluating ABAS plans on the PTVs of the edited structure sets, V95reduced by 7.2% ± 5.4% (1 SD) (p &lt; 0.03). The mean reduction in D99was 14.2 Gy (range 1-54 Gy). Even for Dice coefficients &gt;0.8 and mean contour distances &lt;1 mm, reductions in D99up to 11 Gy were observed. For treatment plans based on observer PTVs and non-edited auto-contoured salivary glands, the mean doses in the edited glands differed by only -0.6 Gy ± 1.0 Gy (p = 0.06). Conclusions: Editing of auto-contoured neck CTVs generated by ABAS is required to avoid large underdosages in target volumes. Often used similarity measures for evaluation of auto-contouring algorithms, such as dice coefficients, do not predict well for expected PTV underdose. Editing of salivary glands is less important as mean doses achieved for non-edited glands predict well for edited structures. </description>
    </item> <item>
      <title>Nasal reconstruction after malignant tumor resection: An algorithm for treatment (Article)</title>
      <link>http://repub.eur.nl/res/pub/25158/</link>
      <pubDate>2011-03-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Late outcome after intracoronary beta radiation brachytherapy: A matched-propensity controlled ten-year follow-up study (Article)</title>
      <link>http://repub.eur.nl/res/pub/26531/</link>
      <pubDate>2011-01-01T00:00:00Z</pubDate>
      <description>Aims: Increased major adverse cardiac events (MACE) beyond six months after intracoronary β radiation brachytherapy (IRBT) are a major concern. The aim of this study was to evaluate the 10-year clinical outcome after IRBT. Methods and results: From 1997 to 2002, 301 consecutive patients treated with IRBT were included prospectively, whereafter 602 control patients treated with conventional percutaneous coronary intervention (PCI) were matched by propensity score methodology. MACE was defined as all-cause death, any myocardial infarction or any revascularisation. Median follow-up duration was 9.7 years. Mortality rates in both groups were similar. Cumulative 5-month, 2-, and 10- year MACE-free survival rates of IRBT patients were 89%, 56% and 29%, respectively, while those of the control patients were 90%, 76% and 52%, respectively (p&lt;0.001). The difference in the MACE rate was mainly driven by target vessel revascularisation (TVR) (p&lt;0.001). Furthermore, two or more repeat TVRs were needed in 12% of IRBT patients and in only 6% of control patients (p&lt;0.01). Adjusted hazard ratios for IRBT-associated all-cause mortality and MACE were 1.0 (95% CI 0.7-1.5) and 1.8 (95% CI 1.5-2.2), respectively. Conclusion: IRBT was associated with increased MACE between five months and two years of follow-up, mainly driven by repeat revascularisations. Similar event rate after two years indicate that there were no very late adverse effects related to IRBT. </description>
    </item> <item>
      <title>Comparison of Macroscopic Pathology Measurements with Magnetic Resonance Imaging and Assessment of Microscopic Pathology Extension for Colorectal Liver Metastases (Article)</title>
      <link>http://repub.eur.nl/res/pub/27980/</link>
      <pubDate>2010-12-23T00:00:00Z</pubDate>
      <description>Purpose: To compare pathology macroscopic tumor dimensions with magnetic resonance imaging (MRI) measurements and to establish the microscopic tumor extension of colorectal liver metastases. Methods and Materials: In a prospective pilot study we included patients with colorectal liver metastases planned for surgery and eligible for MRI. A liver MRI was performed within 48 hours before surgery. Directly after surgery, an MRI of the specimen was acquired to measure the degree of tumor shrinkage. The specimen was fixed in formalin for 48 hours, and another MRI was performed to assess the specimen/tumor shrinkage. All MRI sequences were imported into our radiotherapy treatment planning system, where the tumor and the specimen were delineated. For the macroscopic pathology analyses, photographs of the sliced specimens were used to delineate and reconstruct the tumor and the specimen volumes. Microscopic pathology analyses were conducted to assess the infiltration depth of tumor cell nests. Results: Between February 2009 and January 2010 we included 13 patients for analysis with 21 colorectal liver metastases. Specimen and tumor shrinkage after resection and fixation was negligible. The best tumor volume correlations between MRI and pathology were found for T1-weighted (w) echo gradient sequence (rs= 0.99, slope = 1.06), and the T2-w fast spin echo (FSE) single-shot sequence (rs= 0.99, slope = 1.08), followed by the T2-w FSE fat saturation sequence (rs= 0.99, slope = 1.23), and the T1-w gadolinium-enhanced sequence (rs= 0.98, slope = 1.24). We observed 39 tumor cell nests beyond the tumor border in 12 metastases. Microscopic extension was found between 0.2 and 10 mm from the main tumor, with 90% of the cases within 6 mm. Conclusions: MRI tumor dimensions showed a good agreement with the macroscopic pathology suggesting that MRI can be used for accurate tumor delineation. However, microscopic extensions found beyond the tumor border indicate that caution is needed in selecting appropriate tumor margins. </description>
    </item> <item>
      <title>Clinical Validation of Atlas-Based Auto-Segmentation of Multiple Target Volumes and Normal Tissue (Swallowing/Mastication) Structures in the Head and Neck (Article)</title>
      <link>http://repub.eur.nl/res/pub/23963/</link>
      <pubDate>2010-10-06T00:00:00Z</pubDate>
      <description>Purpose: To validate and clinically evaluate autocontouring using atlas-based autosegmentation (ABAS) of computed tomography images. Methods and Materials: The data from 10 head-and-neck patients were selected as input for ABAS, and neck levels I-V and 20 organs at risk were manually contoured according to published guidelines. The total contouring times were recorded. Two different ABAS strategies, multiple and single subject, were evaluated, and the similarity of the autocontours with the atlas contours was assessed using Dice coefficients and the mean distances, using the leave-one-out method. For 12 clinically treated patients, 5 experienced observers edited the autosegmented contours. The editing times were recorded. The Dice coefficients and mean distances were calculated among the clinically used contours, autocontours, and edited autocontours. Finally, an expert panel scored all autocontours and the edited autocontours regarding their adequacy relative to the published atlas. Results: The time to autosegment all the structures using ABAS was 7 min/patient. No significant differences were observed in the autosegmentation accuracy for stage N0 and N+ patients. The multisubject atlas performed best, with a Dice coefficient and mean distance of 0.74 and 2 mm, 0.67 and 3 mm, 0.71 and 2 mm, 0.50 and 2 mm, and 0.78 and 2 mm for the salivary glands, neck levels, chewing muscles, swallowing muscles, and spinal cord-brainstem, respectively. The mean Dice coefficient and mean distance of the autocontours vs. the clinical contours was 0.8 and 2.4 mm for the neck levels and salivary glands, respectively. For the autocontours vs. the edited autocontours, the mean Dice coefficient and mean distance was 0.9 and 1.6 mm, respectively. The expert panel scored 100% of the autocontours as a "minor deviation, editable" or better. The expert panel scored 88% of the edited contours as good compared with 83% of the clinical contours. The total editing time was 66 min. Conclusion: Multiple-subject ABAS of computed tomography images proved to be a useful novel tool in the rapid delineation of target and normal tissues. Although editing of the autocontours is inevitable, a substantial time reduction was achieved using editing, instead of manual contouring (180 vs. 66 min). </description>
    </item> <item>
      <title>Potentials and limitations of guiding liver stereotactic body radiation therapy set-up on liver-implanted fiducial markers (Article)</title>
      <link>http://repub.eur.nl/res/pub/21215/</link>
      <pubDate>2010-08-01T00:00:00Z</pubDate>
      <description>Purpose: We investigated the potentials and limitations of guiding liver stereotactic body radiation therapy (SBRT) set-up on liver-implanted fiducial markers. Methods and Materials: Twelve patients undergoing compression-supported SBRT in a stereotactic body frame received fluoroscopy at treatment preparation and before each treatment fraction. In fluoroscopic videos we localized the markers and diaphragm tip at expiration and the spine (measurements on free-breathing and abdominal compression). Day-to-day displacements, rotations (markers only), and deformations were determined. Marker guidance was compared to conventional set-up strategies in treatment set-up simulations. Results: For compression, day-to-day motion of markers with respect to their centers of mass (COM) was σ = 0.9 mm (random error SD), ∑ = 0.4 mm (systematic error SD), and &lt;2.1 mm (maximum). Consequently, assuming that markers were closely surrounding spherical tumors, marker COM-guided set-up would have required safety margins of ∼2 mm. Using marker COM as the gold standard, other set-up methods (using no correction, spine registration, and diaphragm tip craniocaudal registration) resulted in set-up errors of 1.4 mm &lt; σ &lt; 2.8 mm, 2.6 mm &lt; ∑ &lt; 5.1 mm, and 6.3 mm &lt; max &lt; 12.4 mm. Day-to-day intermarker motion of &lt;16.7%, 2.2% median, and rotations between 3.5° and 7.2° were observed. For markers not surrounding the tumor, e.g., 5 cm between respective COMs, these changes could effect residual tumor set-up errors up to 8.4 mm, 1.1 mm median (deformations), and 3.1 mm to 6.3 mm (rotations). Compression did not systematically contribute to deformations and rotations, since similar results were observed for free-breathing. Conclusions: If markers can be implanted near and around the tumor, residual set-up errors by marker guidance are small compared to those of conventional set-up methods, allowing high-precision tumor radiation set-up. However, substantial errors may result if markers are not implanted precisely, requiring further research to obtain adequate safety margins.</description>
    </item> <item>
      <title>Clinical introduction of Monte Carlo treatment planning: A different prescription dose for non-small cell lung cancer according to tumor location and size (Article)</title>
      <link>http://repub.eur.nl/res/pub/20256/</link>
      <pubDate>2010-07-01T00:00:00Z</pubDate>
      <description>Purpose: To provide a prescription dose for Monte Carlo (MC) treatment planning in patients with non-small-cell lung cancer according to tumor size and location. Methods: Fifty-three stereotactic radiotherapy plans designed using the equivalent path-length (EPL) algorithm were re-calculated using MC. Plans were compared by the minimum dose to 95% of the PTV (D95), the heterogeneity index (HI) and the mean dose to organs at risk (OARs). Based on changes in D95, the prescription dose was converted from EPL to MC. Based on changes in HI, we examined the feasibility of MC prescription to plans re-calculated but not re-optimized with MC. Results: The MC fraction dose for peripheral tumors is 16-18 Gy depending on tumor size. For central tumors the MC dose was reduced less than for peripheral tumors. The HI decreased on average by 4-9% in peripheral tumors and 3-5% in central tumors. The mean dose to OARs was lower for MC than EPL, and correlated strongly (R2 = 0.98-0.99). Conclusion: For the conversion from EPL to MC we recommend a separate prescription dose according to tumor size. MC optimization is not required if a HI ≥ 70% is accepted. Dose constraints to OARs can be easily converted due to the high EPL-MC correlation.</description>
    </item> <item>
      <title>Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial (Article)</title>
      <link>http://repub.eur.nl/res/pub/20264/</link>
      <pubDate>2010-07-01T00:00:00Z</pubDate>
      <description>Purpose: To investigate the effect of dose escalation within prognostic risk groups in prostate cancer. Patients and methods: Between 1997 and 2003, 664 patients with localized prostate cancer were randomly assigned to receive 68- or 78-Gy of radiotherapy. Two prognostic models were examined: a risk group model (low-, intermediate-, and high-risk) and PSA-level groupings. High-risk patients with hormonal therapy (HT) were analyzed separately. Outcome variable was freedom from failure (FFF) (clinical failure or PSA nadir + 2 μg/L). Results: In relation to the advantage of high-dose radiotherapy, intermediate-risk patients benefited most from dose escalation. However no significant heterogeneity could be demonstrated between the risk groups. For two types of PSA-level groupings: PSA &lt; 10 and ≥10 μg/L, and &lt;8, 8-18 and &gt;8 μg/L, the test for heterogeneity was significant (p = 0.03 and 0.05, respectively). Patients with PSA 8-18 μg/L (n = 297, HR = 0.59) derived the greatest benefit from dose escalation. No heterogeneity could be demonstrated for high-risk patients with and without HT. Conclusion: Intermediate-risk group derived the greatest benefit for dose escalation. However, from this trial no indication was found to exclude low-risk or high-risk patients from high-dose radiotherapy. Patients could be selected for high-dose radiotherapy based on PSA-level groupings: for patients with a PSA &lt; 8 μg/L high-dose radiotherapy is probably not indicated, but should be confirmed in other randomized studies.</description>
    </item> <item>
      <title>Controversies in the treatment of high-risk prostate cancer - What is the optimal combination of hormonal therapy and radiotherapy: A review of literature (Article)</title>
      <link>http://repub.eur.nl/res/pub/27887/</link>
      <pubDate>2010-05-15T00:00:00Z</pubDate>
      <description>BACKGROUND. In high-risk prostate carcinoma, there is controversy whether these patients should be treated with escalated-dose (≥74 Gy) or conventional-dose radiotherapy (&lt;74 Gy) combined with hormonal therapy. Furthermore, the issue of the optimal duration and timing of hormonal therapy are not well crystallized. PATIENTS AND METHODS. A search for evidence from randomized- and large nonrandomized studies in order to address these issues, was therefore initiated. For this purpose, MedLine, EMbase, and PubMed and the data base of the Dutch randomized dose-escalation trial, were consulted. RESULTS AND CONCLUSIONS. From this search it was concluded that the benefit of hormonal therapy in combination with conventional-dose radiotherapy (&lt;74 Gy) in high-risk prostate cancer is evident (Level 2 evidence); Levels 2 and 3 evidence were provided by several studies supporting the use of escalated-dose radiotherapy in high-risk prostate cancer. For the combination of hormonal therapy with escalated-dose radiotherapy in these patients, there is Level 2 evidence for moderately escalated dose (74 Gy) and high escalated dose (≥78 Gy). The optimal duration and timing of hormonal therapy are not well defined. More randomized-controlled trials and meta-analyses are therefore needed to clearly determine the independent role of dose-escalation in high-risk patients treated with hormonal therapy and the optimal duration and timing of hormonal therapy. </description>
    </item> <item>
      <title>Quality of Life After Stereotactic Radiotherapy for Stage I Non-Small-Cell Lung Cancer (Article)</title>
      <link>http://repub.eur.nl/res/pub/27924/</link>
      <pubDate>2010-05-01T00:00:00Z</pubDate>
      <description>Purpose: To determine the impact of stereotactic radiotherapy on the quality of life of patients with inoperable early-stage non-small-cell lung cancer (NSCLC). Overall survival, local tumor control, and toxicity were also evaluated in this prospective study. Methods and Materials: From January 2006 to February 2008, quality of life, overall survival, and local tumor control were assessed in 39 patients with pathologically confirmed T1 to 2N0M0 NSCLC. These patients were treated with stereotactic radiotherapy. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30 and the QLQ LC13 lung cancer-specific questionnaire were used to investigate changes in quality of life. Assessments were done before treatment, at 3 weeks, and at 2, 4, 6, 9, and 12 months after treatment, until death or progressive disease. Toxicity was evaluated using common terminology criteria for adverse events version 3.0. Results: Emotional functioning improved significantly after treatment. Other function scores and QLQ C30 and QLQ LC13 lung symptoms (such as dyspnea and coughing) showed no significant changes. The overall 2-year survival rate was 62%. After a median follow-up of 17 months, 1 patient had a local recurrence (3%). No grade 4 or 5 treatment-related toxicity occurred. Grade 3 toxicity consisted of thoracic pain, which occurred in 1 patient within 4 months of treatment, while it occurred thereafter in 2 patients. Conclusions: Quality of life was maintained, and emotional functioning improved significantly after stereotactic radiotherapy for stage I NSCLC, while survival was acceptable, local tumor control was high, and toxicity was low. </description>
    </item> <item>
      <title>The clinical feasibility of deep hyperthermia treatment in the head and neck (Article)</title>
      <link>http://repub.eur.nl/res/pub/20697/</link>
      <pubDate>2010-04-06T00:00:00Z</pubDate>
      <description>To apply high-quality hyperthermia treatment to tumours at deep locations in the head and neck (H&amp;N), we have designed and built a site-specific phased-array applicator. Earlier, we demonstrated its features in parameter studies, validated those by phantom measurements and clinically introduced the system. In this paper we will critically reviewour first clinical experiences and demonstrate the pivotal role of hyperthermia treatment planning (HTP). Three representative patient cases (thyroid, oropharynx and nasal cavity) are selected and discussed. Treatment planning, the treatment, interstitially measured temperatures and their interrelation are analysed from a physics point of view. Treatments lasting 1 h were feasible and well tolerated and no acute treatment-related toxicity has been observed. Maximum temperatures measured are in the range of those obtained during deep hyperthermia treatments in the pelvic region but mean temperatures are still to be improved. Further, we found that simulated power absorption correlated well with measured temperatures illustrating the validity of our treatment approach of using energy profile
optimizations to arrive at higher  temperatures. This is the first data proving
that focussed heating of tumours in the H&amp;N is feasible. Further, HTP proved
a valuable tool in treatment optimization. Items to improve are (1) the transfer
of HTP settings into the clinic and (2) the registration of the thermal dose,
i.e. dosimetry.</description>
    </item> <item>
      <title>Stereotactic body radiation therapy for colorectal liver metastases (Article)</title>
      <link>http://repub.eur.nl/res/pub/19472/</link>
      <pubDate>2010-03-01T00:00:00Z</pubDate>
      <description>Background: Stereotactic body radiation therapy (SBRT) is a treatment option for colorectal liver metastases. Local control, patient survival and toxicity were assessed in an experience of SBRT for colorectal liver metastases. Methods: SBRT was delivered with curative intent to 20 consecutively treated patients with colorectal hepatic metastases who were candidates for neither resection nor radiofrequency ablation (RFA). The median number of metastases was 1 (range 1-3) and median size was 2-3 (range 0-7-6-2) cm. Toxicity was scored according to the Common Toxicity Criteria version 3.0. Local control rates were derived on tumour-based analysis. Results: Median follow-up was 26 (range 6-57) months. Local failure was observed in nine of 31 lesions after a median interval of 22 (range 12-52) months. Actuarial 2-year local control and survival rates were 74 and 83 per cent respectively. Hepatic toxicity grade 2 or less was reported in 18 patients. Two patients had an episode of hepatic toxicity grade 3. Conclusion: SBRT is a treatment option for patients with colorectal liver metastases who are not candidates for resection or RFA.</description>
    </item> <item>
      <title>The clinical feasibility of deep hyperthermia treatment in the head and neck (Article)</title>
      <link>http://repub.eur.nl/res/pub/20698/</link>
      <pubDate>2010-01-01T00:00:00Z</pubDate>
      <description>To apply high-quality hyperthermia treatment to tumours at deep locations in the head and neck (H&amp;N), we have designed and built a site-specific phased-array applicator. Earlier, we demonstrated its features in parameter studies, validated those by phantom measurements and clinically introduced the system. In this paper we will critically reviewour first clinical experiences and demonstrate the pivotal role of hyperthermia treatment planning (HTP). Three representative patient cases (thyroid, oropharynx and nasal cavity) are selected and discussed. Treatment planning, the treatment, interstitially measured temperatures and their interrelation are analysed from a physics point of view. Treatments lasting 1 h were feasible and well tolerated and no acute treatment-related toxicity has been observed. Maximum temperatures measured are in the range of those obtained during deep hyperthermia treatments in the pelvic region but mean temperatures are still to be improved. Further, we found that simulated power absorption correlated well with measured temperatures illustrating the validity of our treatment approach of using energy profile
optimizations to arrive at higher  temperatures. This is the first data proving
that focussed heating of tumours in the H&amp;N is feasible. Further, HTP proved
a valuable tool in treatment optimization. Items to improve are (1) the transfer
of HTP settings into the clinic and (2) the registration of the thermal dose,
i.e. dosimetry.</description>
    </item> <item>
      <title>Three-Dimensional Dose Addition of External Beam Radiotherapy and Brachytherapy for Oropharyngeal Patients Using Nonrigid Registration (Article)</title>
      <link>http://repub.eur.nl/res/pub/21881/</link>
      <pubDate>2010-01-01T00:00:00Z</pubDate>
      <description>Purpose: To develop and evaluate a method for adding dose distributions of combined external beam radiotherapy (EBRT) and brachytherapy (BT) for oropharyngeal patients. Methods and Materials: Two computed tomography (CT) scans were used for 5 patients: the EBRT CT, used for EBRT planning, and the BT CT, acquired after catheter implantation. For each scan, the salivary glands and the chewing and swallowing muscles were contoured, and a dose distribution was calculated. A nonrigid transformation was obtained by registering the organs' surfaces. Then the BT dose distribution was mapped onto the EBRT dose distribution by applying the transformation obtained. To account for differences in fractionation, the physical doses were converted to equivalent dose in 2 Gy (EQD2), and the total dose was found by adding dose voxel by voxel. The robustness of the dose addition was investigated by varying delineations and input parameters of the registration method and by varying the α/β parameter for EQD2. The effect of the perturbations was quantified using dose-volume histograms (DVH) and gamma analyses (distance-to-agreement/dose-difference = 1 mm/1 Gy). Results: The variations in input parameters and delineations caused only small perturbations in the DVH of the added dose distributions. For most organs the gamma index was low, and it was moderately elevated for organs lying in areas with a steep gradient (median gamma index ≤2.3 for constrictor muscles, ≤0.7 for all other organs). Conclusions: The presented method allows adding dose distributions of combined EBRT and BT for oropharyngeal patients. In general, the method is reliable and robust with respect to uncertainties in organ delineation, perturbations in input parameters of the method, and α/β values.</description>
    </item> <item>
      <title>Stability of Markers Used for Real-Time Tumor Tracking After Percutaneous Intrapulmonary Placement (Article)</title>
      <link>http://repub.eur.nl/res/pub/23254/</link>
      <pubDate>2010-01-01T00:00:00Z</pubDate>
      <description>Purpose: To determine the stability of markers used for real-time tumor tracking after percutaneous intrapulmonary placement. Methods and Materials: A total of 42 patients with 44 lesions, 111 markers, and ≥2 repeat computed tomography (CT) scans were studied. The tumor on the repeat CT scans was registered with the tumor on the planning CT scan. Next, the three-dimensional marker coordinates were determined on the planning CT scan and repeat CT scans. Marker stability was analyzed by the displacement of the markers and the displacement of the center of mass (COM) of the marker configurations. In addition, we assessed the reliability of using the intermarker distance as a check for displacements in the COM of the marker configurations. Results: The median marker displacement was 1.3 mm (range, 0.1-53.6). The marker displacement was &gt;5 mm in 12% of the markers and &gt;10 mm in 5% of the markers. The causes of marker displacement &gt;5 mm included marker migration (2 of 13) and target volume changes (5 of 13). Nonsynchronous tumor and marker movement during breathing might have been responsible for the displacements &gt;5 mm in the other 6 of 13 markers. The median displacement in the COM of the marker configurations was 1.0 mm (range, 0.1-23.3). Displacements in the COM of the marker configurations of ≥2.0 mm were detected by changes in the intermarker distance of &gt;1.5 mm in 96% of the treatment fractions. Conclusion: The median marker displacement was small (1.3 mm). Nevertheless, displacements &gt;5 mm occurred in 12% of the markers. Therefore, we recommend the implantation of multiple markers because multiple markers will enable a quick and reliable check of marker displacement by determining the change in the intermarker distance. A displacement in the COM of the marker configuration of ≥2.0 mm was almost always detected (96%) by a change in the distance between the markers of &gt;1.5 mm. This enabled the displaced marker to be disabled, such that tumor localization was not compromised.</description>
    </item> <item>
      <title>Re: "The safety and efficacy of robotic image-guided radiosurgery system treatment for intra- and extracranial lesions: A systematic review of the literature" [Radiotherapy and Oncology 89 (2009) 245-253] (Article)</title>
      <link>http://repub.eur.nl/res/pub/27034/</link>
      <pubDate>2009-12-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Stereotactic Body Radiation Therapy for Liver Tumors: Impact of Daily Setup Corrections and Day-to-Day Anatomic Variations on Dose in Target and Organs at Risk (Article)</title>
      <link>http://repub.eur.nl/res/pub/24395/</link>
      <pubDate>2009-11-15T00:00:00Z</pubDate>
      <description>Purpose: To assess day-to-day differences between planned and delivered target volume (TV) and organ-at-risk (OAR) dose distributions in liver stereotactic body radiation therapy (SBRT), and to investigate the dosimetric impact of setup corrections. Methods and Materials: For 14 patients previously treated with SBRT, the planning CT scan and three treatment scans (one for each fraction) were included in this study. For each treatment scan, two dose distributions were calculated: one using the planned setup for the body frame (no correction), and one using the clinically applied (corrected) setup derived from measured tumor displacements. Per scan, the two dose distributions were mutually compared, and the clinically delivered distribution was compared with planning. Doses were recalculated in equivalent 2-Gy fraction doses. Statistical analysis was performed with the linear mixed model. Results: With setup corrections, the mean loss in TV coverage relative to planning was 1.7%, compared with 6.8% without corrections. For calculated equivalent uniform doses, these figures were 2.3% and 15.5%, respectively. As for the TV, mean deviations of delivered OAR doses from planning were small (between -0.4 and +0.3 Gy), but the spread was much larger for the OARs. In contrast to the TV, the mean impact of setup corrections on realized OAR doses was close to zero, with large positive and negative exceptions. Conclusions: Daily correction of the treatment setup is required to obtain adequate TV coverage. Because of day-to-day patient anatomy changes, large deviations in OAR doses from planning did occur. On average, setup corrections had no impact on these doses. Development of new procedures for image guidance and adaptive protocols is warranted. </description>
    </item> <item>
      <title>Hypofractionated radiotherapy denoted as the "christie scheme": An effective means of palliating patients with head and neck cancers not suitable for curative treatment (Article)</title>
      <link>http://repub.eur.nl/res/pub/24611/</link>
      <pubDate>2009-11-06T00:00:00Z</pubDate>
      <description>Objectives. A prospective study of the efficacy and toxicity profile of patients with squamous cell carcinoma of the head and neck (HNSCC) without curative treatment options treated consistently with hypofractionated radiotherapy schedule. Patients and methods. Between 1995 and 2006, 158 patients with HNSCC, unsuitable for curative treatment, were treated with a hypofractionated scheme of radiotherapy consisting of 16 fractions of 3.125 Gy. Endpoints of the study were response rates, loco-regional control, disease-free survival, overall survival, acute and late toxicity, and quality of life (QoL). Results. Seventy four percent of patients were male, 31% had oropharyngeal cancer and 81% stage IV disease. With 45% complete response and 28% partial response an overall response rate of 73% was achieved, 6% had stable disease, and 21% progressed during or directly after completion of treatment. Median survival time was 17 months and 62 patients (40%) survived ≥1 year after RT. The actuarial rates of loco-regional control, disease-free survival and overall survival were 62%, 32% and 40% at 1-year, respectively and 32%, 14% and 17% at 3-years, respectively. Acute grade ≥3 skin and mucosal toxicities were observed in 45% and 65% of patients, respectively. Severe late toxicity was reported in 4.5% of patients. Of patients surviving ≥1 year after RT, retrospective chart review showed that 50% gained weight, pain improved in 77%, performance status in 47% and only 29% of them was still feeding-tube dependent. Conclusions. Our hypofractionated radiotherapy scheme is an effective, well-tolerated and safe palliative schedule in HNSCC who are unsuitable for curative treatment options. Using 3.125 Gy per fraction (Christie scheme), excellent palliation was achieved resulting in acceptable response rates, excellent symptom control, acceptable toxicity profile, and good QoL of patients surviving ≥1 year after completion of treatment.</description>
    </item> <item>
      <title>Early Hyperbaric Oxygen Therapy for Reducing Radiotherapy Side Effects: Early Results of a Randomized Trial in Oropharyngeal and Nasopharyngeal Cancer (Article)</title>
      <link>http://repub.eur.nl/res/pub/24394/</link>
      <pubDate>2009-11-01T00:00:00Z</pubDate>
      <description>Purpose: Comparison of quality of life (QoL) and side effects in a randomized trial for early hyperbaric oxygen therapy (HBOT) after radiotherapy (RT). Methods and Materials: From 2006, 19 patients with tumor originating from the tonsillar fossa and/or soft palate (15), base of tongue (1), and nasopharynx (3) were randomized to receive HBOT or not. HBOT consisted of 30 sessions at 2.5 ATA (15 msw) with oxygen breathing for 90 min daily, 5 days per week, applied shortly after the RT treatment was completed. As of 2005, all patients received validated questionnaires (i.e., the European Organization for Research and Treatment of Cancer [EORTC] QLQ-C30, EORTC QLQ Head and Neck Cancer Module (H&amp;N35), Performance Status Scale): before treatment; at the start of RT treatment; after 46 Gy; at the end of RT treatment; and 2, 4, and 6 weeks and 3, 6, 12, and 18 months after follow-up. Results: On all QoL items, better scores were obtained in patients treated with hyperbaric oxygen. The difference between HBOT vs. non-HBOT was significant for all parameters: EORTC H&amp;N35 Swallowing (p = 0.011), EORTC H&amp;N35 Dry Mouth (p = 0.009), EORTC H&amp;N35, Sticky Saliva (p = 0.01), PSS Eating in Public (p = 0.027), and Pain in Mouth (visual analogue scale; p &lt; 0.0001). Conclusions: Patients randomized for receiving hyperbaric oxygen after the RT had better QoL scores for swallowing, sticky saliva, xerostomia, and pain in mouth. </description>
    </item> <item>
      <title>On-line cone beam CT image guidance for vocal cord tumor targeting (Article)</title>
      <link>http://repub.eur.nl/res/pub/24504/</link>
      <pubDate>2009-10-01T00:00:00Z</pubDate>
      <description>Background and purpose: We are developing a technique for highly focused vocal cord irradiation in early glottic carcinoma to optimally treat a target volume confined to a single cord. This technique, in contrast with the conventional methods, aims at sparing the healthy vocal cord. As such a technique requires sub-mm daily targeting accuracy to be effective, we investigate the accuracy achievable with on-line kV-cone beam CT (CBCT) corrections. Materials and methods: CBCT scans were obtained in 10 early glottic cancer patients in each treatment fraction. The grey value registration available in X-ray volume imaging (XVI) software (Elekta, Synergy) was applied to a volume of interest encompassing the thyroid cartilage. After application of the thus derived corrections, residue displacements with respect to the planning CT scan were measured at clearly identifiable relevant landmarks. The intra- and inter-observer variations were also measured. Results: While before correction the systematic displacements of the vocal cords were as large as 2.4 ± 3.3 mm (cranial-caudal population mean ± SD Σ), daily CBCT registration and correction reduced these values to less than 0.2 ± 0.5 mm in all directions. Random positioning errors (SD σ) were reduced to less than 1 mm. Correcting only for translations and not for rotations did not appreciably affect this accuracy. The residue random displacements partly stem from intra-observer variations (SD = 0.2-0.6 mm). Conclusion: The use of CBCT for daily image guidance in combination with standard mask fixation reduced systematic and random set-up errors of the vocal cords to &lt;1 mm prior to the delivery of each fraction dose. Thus, this facilitates the high targeting precision required for a single vocal cord irradiation. </description>
    </item> <item>
      <title>A novel flexible framework with automatic feature  correspondence optimization for nonrigid registration in radiotherapy (Article)</title>
      <link>http://repub.eur.nl/res/pub/22195/</link>
      <pubDate>2009-07-01T00:00:00Z</pubDate>
      <description>Technical improvements in planning and dose delivery and in verification of patient positioning have substantially widened the therapeutic window for radiation treatment of cancer. However, changes in patient anatomy during the treatment limit the exploitation of these new techniques. To further improve radiation treatments, anatomical changes need to be modeled and accounted for. Non-rigid registration can be used for this purpose. This paper describes the design, the implementation and the validation of a new framework for non-rigid registration for radiotherapy applications. The core of this framework is an improved version of the Thin Plate Splines Robust Point Matching (TPS-RPM) algorithm. The TPS-RPM algorithm estimates a global correspondence and a transformation between the points that represent organs of interest belonging to two image sets. However, the algorithm does not allow for the inclusion of prior knowledge on the correspondence of subset of points and therefore, it can lead to inconsistent anatomical solutions. In this paper TPS-RPM was improved by employing a novel correspondence filter that supports simultaneous registration of multiple structures. The improved method allows for coherent organ registration and for the inclusion of user defined landmarks, lines and surfaces inside and outside of structures of interest. A procedure to generate control points form segmented organs is described. The framework parameters r and ?, which control the number of points and the non-rigidness of the transformation  respectively, were optimized for three sites with different degrees of deformation: head and neck, prostate and cervix, using two cases per site. For the head and neck cases, the salivary glands were manually contoured on CT-scans, for the prostate cases the prostate and the vesicles, and for the cervix cases the cervix-uterus, the bladder and the rectum. The transformation error obtained using the best set of parameters was below 1 mm for all the studied cases. The length of the deformation vectors were on average (± 1 standard deviation) 5.8 ± 2.5 and 2.6 ± 1.1 mm for the head and neck cases, 7.2 ± 4.5 and 8.6 ± 1.9 mm for the prostate cases, and 19.0 ± 11.6 and 14.5 ± 9.3 mm for the cervix cases. Distinguishable anatomical features were identified for each case, and were used to validate the registration by calculating residual distances after transformation: 1.5 ± 0.8, 2.3 ± 1.0 and 6.3 ± 2.9 mm for the head and neck, prostate and cervix sites respectively. Finally, we demonstrated how the inclusion of these anatomical features in the registration process reduced the residual distances to 0.8 ± 0.5, 0.6 ± 0.5 and 1.3 ± 0.7 mm for the head and neck, prostate and cervix sites respectively. The inclusion of additional anatomical features produced more anatomically coherent transformations without compromising the transformation error. We concluded that the presented non-rigid registration framework is a powerful tool to simultaneously register multiple segmented organs with very different complexity.</description>
    </item> <item>
      <title>A novel flexible framework with automatic feature  correspondence optimization for nonrigid registration in radiotherapy (Article)</title>
      <link>http://repub.eur.nl/res/pub/22197/</link>
      <pubDate>2009-07-01T00:00:00Z</pubDate>
      <description>Technical improvements in planning and dose delivery and in verification of patient positioning have substantially widened the therapeutic window for radiation treatment of cancer. However, changes in patient anatomy during the treatment limit the exploitation of these new techniques. To further improve radiation treatments, anatomical changes need to be modeled and accounted for. Non-rigid registration can be used for this purpose. This paper describes the design, the implementation and the validation of a new framework for non-rigid registration for radiotherapy applications. The core of this framework is an improved version of the Thin Plate Splines Robust Point Matching (TPS-RPM) algorithm. The TPS-RPM algorithm estimates a global correspondence and a transformation between the points that represent organs of interest belonging to two image sets. However, the algorithm does not allow for the inclusion of prior knowledge on the correspondence of subset of points and therefore, it can lead to inconsistent anatomical solutions. In this paper TPS-RPM was improved by employing a novel correspondence filter that supports simultaneous registration of multiple structures. The improved method allows for coherent organ registration and for the inclusion of user defined landmarks, lines and surfaces inside and outside of structures of interest. A procedure to generate control points form segmented organs is described. The framework parameters r and ?, which control the number of points and the non-rigidness of the transformation  respectively, were optimized for three sites with different degrees of deformation: head and neck, prostate and cervix, using two cases per site. For the head and neck cases, the salivary glands were manually contoured on CT-scans, for the prostate cases the prostate and the vesicles, and for the cervix cases the cervix-uterus, the bladder and the rectum. The transformation error obtained using the best set of parameters was below 1 mm for all the studied cases. The length of the deformation vectors were on average (± 1 standard deviation) 5.8 ± 2.5 and 2.6 ± 1.1 mm for the head and neck cases, 7.2 ± 4.5 and 8.6 ± 1.9 mm for the prostate cases, and 19.0 ± 11.6 and 14.5 ± 9.3 mm for the cervix cases. Distinguishable anatomical features were identified for each case, and were used to validate the registration by calculating residual distances after transformation: 1.5 ± 0.8, 2.3 ± 1.0 and 6.3 ± 2.9 mm for the head and neck, prostate and cervix sites respectively. Finally, we demonstrated how the inclusion of these anatomical features in the registration process reduced the residual distances to 0.8 ± 0.5, 0.6 ± 0.5 and 1.3 ± 0.7 mm for the head and neck, prostate and cervix sites respectively. The inclusion of additional anatomical features produced more anatomically coherent transformations without compromising the transformation error. We concluded that the presented non-rigid registration framework is a powerful tool to simultaneously register multiple segmented organs with very different complexity.</description>
    </item> <item>
      <title>Multimodality treatment for anaplastic thyroid carcinoma - Treatment outcome in 75 patients (Article)</title>
      <link>http://repub.eur.nl/res/pub/24502/</link>
      <pubDate>2009-07-01T00:00:00Z</pubDate>
      <description>Purpose: To retrospectively analyze the outcome of patients with anaplastic thyroid carcinoma (ATC) treated in the Erasmus MC. Material and methods: Seventy-five ATC-patients were treated between 1972 and 2003. Mean age was 68 years. Tumor stage was IVA in 9%, IVB in 51%, and IVC in 40%. Thirty-six patients underwent up-front surgery, with 53% resulting in R0/R1 resection. Before 1988 adjuvant treatment consisted of conventional radiotherapy (RT) and/or chemotherapy (CT). As of 1988, 30 eligible patients were enrolled in a newly designed protocol. This consists of locoregional RT in 46 fractions of 1.1 Gy, given twice daily, followed by prophylactic irradiation of the lungs (PLI) in 5 daily fractions of 1.5 Gy. During radiation, low-dose Doxorubicine (15 mg/m2) is administered weekly and is followed by adjuvant Doxorubicine (50 mg/m2) 3-weekly up to a cumulative dose of 550 mg/m2. Twenty-five ineligible patients were treated conventionally. Results: Overall median survival was 3 months, 1-year OS 9%. Locoregional control was significantly higher in patients who had undergone R0/R1 resection or chemoradiation, with best results for patients who underwent both (complete remission in 89%). However, the survival benefit of patients who reached CR remained borderline (median OS 7 months, 1-year OS 32%). Three patients survived for more than 5 years; all had undergone R0/R1 surgical resection and chemoradiation. Acute toxicity in the protocol group was significantly higher than in the nonprotocol group, with 46% versus 11% grade 3 pharyngeal and/or esophageal toxicity. Conclusion: Despite the ultimately dismal prognosis of ATC-patients, multimodality treatment significantly improved local control and improved the median survival. </description>
    </item> <item>
      <title>Lacrimal Gland Radiosensitivity in Uveal Melanoma Patients (Article)</title>
      <link>http://repub.eur.nl/res/pub/24393/</link>
      <pubDate>2009-06-01T00:00:00Z</pubDate>
      <description>Purpose: To find a dose-volume effect for inhomogeneous irradiated lacrimal glands. Methods and Materials: Between 1999 and 2006, 72 patients (42 men and 30 women) were treated with fractionated stereotactic radiotherapy in a prospective, nonrandomized clinical trial (median follow-up, 32 months). A total dose of 50 Gy was given on 5 consecutive days. The mean of all Schirmer test results obtained ≥6 months after treatment was correlated with the radiation dose delivered to the lacrimal gland. Also, the appearance of dry eye syndrome (DES) was related to the lacrimal gland dose distribution. Results: Of the 72 patients, 17 developed a late Schirmer value &lt;10 mm; 9 patients developed DES. A statistically significant relationship was found between the received median dose in the lacrimal gland vs. reduced tear production (p = 0.000) and vs. the appearance of DES (p = 0.003), respectively. A median dose of 7 Gy/fraction to the lacrimal gland caused a 50% risk of low Schirmer results. A median dose of 10 Gy resulted in a 50% probability of DES. Conclusion: We found a clear dose-volume relationship for irradiated lacrimal glands with regard to reduced tear production and the appearance of DES. </description>
    </item> <item>
      <title>Clinical Accuracy of the Respiratory Tumor Tracking System of the CyberKnife: Assessment by Analysis of Log Files (Article)</title>
      <link>http://repub.eur.nl/res/pub/24396/</link>
      <pubDate>2009-05-01T00:00:00Z</pubDate>
      <description>Purpose: To quantify the clinical accuracy of the respiratory motion tracking system of the CyberKnife treatment device. Methods and Materials: Data in log files of 44 lung cancer patients treated with tumor tracking were analyzed. Errors in the correlation model, which relates the internal target motion with the external breathing motion, were quantified. The correlation model error was compared with the geometric error obtained when no respiratory tracking was used. Errors in the prediction method were calculated by subtracting the predicted position from the actual measured position after 192.5 ms (the time lag to prediction in our current system). The prediction error was also measured for a time lag of 115 ms and a new prediction method. Results: The mean correlation model errors were less than 0.3 mm. Standard deviations describing intrafraction variations around the whole-fraction mean error were 0.2 to 1.9 mm for cranio-caudal, 0.1 to 1.9 mm for left-right, and 0.2 to 2.5 mm for anterior-posterior directions. Without the use of respiratory tracking, these variations would have been 0.2 to 8.1 mm, 0.2 to 5.5 mm, and 0.2 to 4.4 mm. The overall mean prediction error was small (0.0 ± 0.0 mm) for all directions. The intrafraction standard deviation ranged from 0.0 to 2.9 mm for a time delay of 192.5 ms but was halved by using the new prediction method. Conclusions: Analyses of the log files of real clinical cases have shown that the geometric error caused by respiratory motion is substantially reduced by the application of respiratory motion tracking. </description>
    </item> <item>
      <title>GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas (Article)</title>
      <link>http://repub.eur.nl/res/pub/24500/</link>
      <pubDate>2009-05-01T00:00:00Z</pubDate>
      <description>Both primary and recurrent squamous cell carcinoma of the head and neck are classic indications for brachytherapy. A high rate of local tumor control at the cost of limited morbidity can be achieved with brachytherapy through good patient selection, meticulous source implantation and careful treatment planning. However, no randomized trials have been performed, and there is scant evidence in the literature especially regarding practical clinical recommendations for brachytherapy for head and neck subsites. The Head and Neck Working Group of the European Brachytherapy Group (Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) therefore decided to formulate the present consensus recommendations for low-dose rate, pulsed-dose rate and high-dose rate brachytherapy. The use of brachytherapy in combination with external beam radiotherapy and/or surgery is also covered as well as the use of brachytherapy in previously irradiated patients. Given the paucity of evidence in the literature, these recommendations are mainly based on clinical experience accumulated by the members of the working group over several decades and the respective publications. The recommendations cover in a general part (1) patient selection, the pre-treatment work up and patient care, (2) treatment strategy, (3) target definition, (4) implant techniques, (5) dose and dose rate prescription, (6) treatment planning and reporting, (7) treatment monitoring (8) catheter removal, and (9) post-treatment patient care and follow-up. The recommendations are then specified for the classical brachytherapy tumor sites following an analogue more focussed structure (patient selection, implant technique, target definition, dose and dose rate prescription, results): lip, oral mucosa, mobile tongue, floor of mouth, oropharynx, nasopharynx, paranasal sinuses. </description>
    </item> <item>
      <title>Quality of life of oropharyngeal cancer patients treated with brachytherapy (Article)</title>
      <link>http://repub.eur.nl/res/pub/18439/</link>
      <pubDate>2009-02-23T00:00:00Z</pubDate>
      <description>Brachytherapy (BT) is a highly conformal (accurate clinical target volume delineation, no planning target volume margin) radiotherapy technique; the radioactive source, guided by afterloading catheters, is implanted into the heart of the tumor. The localized high dose of radiation enables high tumor control rates and, because of rapid dose fall-off, sparing of the adjacent normal tissues. At the Erasmus Medical Center, excellent results were observed: 5-year local regional control of 84%, 5-year disease-free survival of 59%, and 5-year overall survival of 64%. Therefore, in the case of moderately sized tumors, for well-trained, skillful physicians, BT is the therapy of choice (if technically feasible). However, side effects are not totally negligible, partly because of the cumulative dose of BT and the first series of 46/2 Gy. However, patients treated with BT still have a better swallowing-related quality of life, which might improve further if summation of BT and the first series of 46/2 Gy, as well as autocontouring of the neck levels, are realized. So far, there is no significant relationship between the quality index of the BT implants and local control/overall survival and/or quality of life.</description>
    </item> <item>
      <title>Treatment Techniques and Site Considerations Regarding Dysphagia-Related Quality of Life in Cancer of the Oropharynx and Nasopharynx (Article)</title>
      <link>http://repub.eur.nl/res/pub/29732/</link>
      <pubDate>2008-11-15T00:00:00Z</pubDate>
      <description>Purpose: To assess the relationship for oropharyngeal (OP) cancer and nasopharyngeal (NP) cancer between the dose received by the swallowing structures and the dysphagia related quality of life (QoL). Methods and Materials: Between 2000 and 2005, 85 OP and 47 NP cancer patients were treated by radiation therapy. After 46 Gy, OP cancer is boosted by intensity-modulated radiation therapy (IMRT), brachytherapy (BT), or frameless stereotactic radiation/cyberknife (CBK). After 46 Gy, the NP cancer was boosted with parallel-opposed fields or IMRT to a total dose of 70 Gy; subsequently, a second boost was given by either BT (11 Gy) or stereotactic radiation (SRT)/CBK (11.2 Gy). Sixty OP and 21 NP cancer patients responded to functional and QoL questionnaires (i.e., the Performance Status Scales, European Organization for Research and Treatment of Cancer H&amp;N35, and M.D. Anderson Dysphagia Inventory). The swallowing muscles were delineated and the mean dose calculated using the original three-dimensional computed tomography-based treatment plans. Univariate analyses were performed using logistic regression analysis. Results: Most dysphagia problems were observed in the base of tongue tumors. For OP cancer, boosting with IMRT resulted in more dysphagia as opposed to BT or SRT/CBK. For NPC patients, in contrast to the first booster dose (46-70 Gy), no additional increase of dysphagia by the second boost was observed. Conclusions: The lowest mean doses of radiation to the swallowing muscles were achieved when using BT as opposed to SRT/CBK or IMRT. For the 81 patients alive with no evidence of disease for at least 1 year, a dose-effect relationship was observed between the dose in the superior constrictor muscle and the "normalcy of diet" (Performance Status Scales) or "swallowing scale" (H&amp;N35) scores (p &lt; 0.01). </description>
    </item> <item>
      <title>Longitudinal changes in quality of life and costs in long-term survivors of tumors of the oropharynx treated with brachytherapy or surgery (Article)</title>
      <link>http://repub.eur.nl/res/pub/23529/</link>
      <pubDate>2008-10-01T00:00:00Z</pubDate>
      <description>PURPOSE: Based on earlier studies we were interested in finding out if longitudinal assessment of quality of life (QoL) and costs in long-term survivors of oropharyngeal cancers treated with external beam radiation therapy and brachytherapy (BT) or surgery and postoperative radiotherapy showed a change in QoL over the years. Besides, we were curious to know how much the costs per life year and the QALY would be for this patient group.
METHODS AND MATERIALS: Performance status scales: eating in public, understandability of speech, normalcy of diet, xerostomia and ability to swallow were determined in 2003 and 2005. In 2005, the responses to EORTC QLQ-C30, EORTC H&amp;N35, and the Euroqol questionnaire were also measured. Costs and quality-adjusted life years (QALYs) were calculated.
RESULTS: Eating in public, understandability of speech, and normalcy of diet significantly differed in favor of BT. Surgical patients experienced more speech, teeth, and mouth-opening problems. Mean costs and QALYs for BT were V16,112 and V56,060 and for surgery V26,590 and V93,275, respectively.
CONCLUSIONS: QoL scores don’t change over time. Due to the number of admission days, surgery is more costly. Difference in costs for QALYs in favor of BT was observed.</description>
    </item> <item>
      <title>Four-dimensional CT analysis of vocal cords mobility for highly focused single vocal cord irradiation (Article)</title>
      <link>http://repub.eur.nl/res/pub/29350/</link>
      <pubDate>2008-10-01T00:00:00Z</pubDate>
      <description>Background and Purpose: To quantify respiratory motion of the vocal cords during normal respiration using 4D-CT. The final goal is to develop a technique for single vocal cord irradiation (SVCI) in early glottic carcinoma. Sparing the non-involved cord and surrounding structures has the potential to preserve voice quality and allow re-irradiation of recurrent and second primary tumors. Material and methods: Four-dimensional CTs of 1 mm slice thickness from 10 early glottic carcinoma patients were acquired. The lateral dimensions of the air gap separating the vocal cords were measured anteriorly, at mid-level and posteriorly at each phase of the 4D-CTs. The corresponding anterior-posterior gaps were similarly measured. Cranio-caudal vocal cords movements during breathing were derived from the shifts of the arythenoids. Results: The population-averaged mean gap size ± the corresponding standard deviation due to breathing (SDB) for the lateral gaps was 5.8 ± 0.7 mm anteriorly, 8.7 ± 0.9 mm at mid-level, and 11.0 ± 1.3 mm posteriorly. Anterior-posterior gap values were 21.7 ± 0.7 mm, while cranio-caudal shift SDBwas 0.8 mm. Conclusion: Vocal cords breathing motions were found to be small relative to their separation. Hence, breathing motion does not seem to be a limiting factor for SVCI. </description>
    </item> <item>
      <title>Results of fiberoptic endoscopic evaluation of swallowing vs. radiation dose in the swallowing muscles after radiotherapy of cancer in the oropharynx (Article)</title>
      <link>http://repub.eur.nl/res/pub/29398/</link>
      <pubDate>2008-10-01T00:00:00Z</pubDate>
      <description>Background and purpose: Dysphagia is a serious complaint but frequently underreported. This paper assesses for oropharyngeal cancer (OPC) the relationship between the dose received by the swallowing structures, and the findings of a fiberoptic endoscopic evaluation of the swallowing process (FEES). Materials and methods: Between 2000 and 2005, 60 of 67 OPC patients local-regionally NED for at least one year following treatment responded to three types of QoL questionnaires; i.e. Performance Status Scales, EORTC H&amp;N35, and M.D. Anderson Dysphagia Inventory. Twenty-four patients agreed to the FEES procedure. The main swallowing muscles were delineated, with the mean dose per muscle calculated using the original 3D CT-based treatment plans. Regression analysis was performed between FEES variables and the doses in the different swallowing muscles and the dysphagia related questionnaires. Results: A significant relationship was found between the results of FEES and the mean dose in the superior constrictor muscle (SCM). Some of the subjective dysphagia complaints were significantly correlated with the FEES variables in this retrospectively study. Conclusion: A higher dose in the SCM generally results in worsening of the findings obtained by the FEES examination. </description>
    </item> <item>
      <title>Longitudinal changes in quality of life and costs in long-term survivors of tumors of the oropharynx treated with brachytherapy or surgery (Article)</title>
      <link>http://repub.eur.nl/res/pub/33117/</link>
      <pubDate>2008-10-01T00:00:00Z</pubDate>
      <description>Purpose: Based on earlier studies we were interested in finding out if longitudinal assessment of quality of life (QoL) and costs in long-term survivors of oropharyngeal cancers treated with external beam radiation therapy and brachytherapy (BT) or surgery and postoperative radiotherapy showed a change in QoL over the years. Besides, we were curious to know how much the costs per life year and the QALY would be for this patient group. Methods and materials: Performance status scales: eating in public, understandability of speech, normalcy of diet, xerostomia and ability to swallow were determined in 2003 and 2005. In 2005, the responses to EORTC QLQ-C30, EORTC H&amp;N35, and the Euroqol questionnaire were also measured. Costs and quality-adjusted life years (QALYs) were calculated. Results: Eating in public, understandability of speech, and normalcy of diet significantly differed in favor of BT. Surgical patients experienced more speech, teeth, and mouth-opening problems. Mean costs and QALYs for BT were €16,112 and €56,060 and for surgery €26,590 and €93,275, respectively. Conclusions: QoL scores don't change over time. Due to the number of admission days, surgery is more costly. Difference in costs for QALYs in favor of BT was observed. </description>
    </item> <item>
      <title>Cardiac metastases (Article)</title>
      <link>http://repub.eur.nl/res/pub/30247/</link>
      <pubDate>2008-08-01T00:00:00Z</pubDate>
      <description>We report a case of esophageal cancer with symptomatic metastases to the heart; the patient was treated with short-course radiotherapy with good symptomatic relief. We reviewed the current literature regarding the epidemiology, clinical presentation, diagnostic tools, treatment modalities, and the prognosis of cardiac metastases. In this report we summarize the most recent autopsy studies (published between 1975 and 2007), in which we found an autopsy incidence of cardiac metastases of 2.3% among the general population, while the incidence among autopsies of cancer patients was 7.1%. Therefore, we share the opinion with others that there has been an increase in the incidence of cardiac metastases among cancer patients diagnosed after 1970, in comparison with the reported incidences in older series before 1970 (7.1% vs 3.8%; Kruskal-Wallis rank test; P = 0.039). Special attention was given to the role of radiotherapy in the management of cardiac metastases. </description>
    </item> <item>
      <title>Reduction of Respiratory Liver Tumor Motion by Abdominal Compression in Stereotactic Body Frame, Analyzed by Tracking Fiducial Markers Implanted in Liver (Article)</title>
      <link>http://repub.eur.nl/res/pub/29677/</link>
      <pubDate>2008-07-01T00:00:00Z</pubDate>
      <description>Purpose: To investigate in a three-dimensional framework the effectiveness and reproducibility of reducing the respiratory motion of liver tumors using abdominal compression in a stereotactic body frame. Methods and Materials: A total of 12 patients with liver tumors, who were treated with stereotactic body radiotherapy, were included in this study. These patients had three gold fiducial markers implanted in the healthy liver tissue surrounding the tumor. Fluoroscopic videos were acquired on the planning day and before each treatment fraction to visualize the motion of the fiducial markers during free breathing and varying levels of abdominal compression. Software was developed to track the fiducial markers and measure their excursions. Results: Abdominal compression reduced the patient group median excursion by 62% in the craniocaudal and 38% in the anteroposterior direction with respect to the median free-breathing excursions. In the left-right direction, the median excursion increased 15% (maximal increase 1.6 mm). The median residual excursion was 4.1 mm in the craniocaudal, 2.4 mm in the anteroposterior, and 1.8 mm in the left-right direction. The mean excursions were reduced by compression to &lt;5 mm in all patients and all directions, with two exceptions (craniocaudal excursion reduction of 20.5 mm to 7.4 mm and of 21.1 mm to 5.9 mm). The residual excursions reproduced well during the treatment course, and the craniocaudal excursions measured on the treatment days were never significantly (α = 0.05) greater than on the planning days. Fine tuning the compression did not considerably change the excursion on the treatment days. Conclusions: Abdominal compression effectively reduced liver tumor motion, yielding small and reproducible excursions in three dimensions. The compression level established at planning could have been safely used on the treatment days. </description>
    </item> <item>
      <title>Analysis of the motion of oropharyngeal tumors and consequences in planning target volume determination (Article)</title>
      <link>http://repub.eur.nl/res/pub/29377/</link>
      <pubDate>2008-05-01T00:00:00Z</pubDate>
      <description>Purpose: To determine adequate three-dimensional (3D) margins around the clinical target volume (CTV) of oropharyngeal cancers. Methods and materials: The CTV, bounded by implanted markers, was recorded under fluoroscopy in antero-posterior (AP) and lateral view. The peak-to-peak motion was measured in lateral, AP and cranio-caudal (CC) directions. Results: During swallowing, the mean amplitude of motion measured was 9.4 mm (0.9-18.5) and 4.1 mm (0.6-11.4) in AP view in the CC and lateral direction, respectively; and 8.6 mm (0.5-16.5) and 7.6 mm (0.9-14.5) in lateral view in the CC and AP direction, respectively. In the non-swallowing period the motion was 1.5 mm (0.3-3.2) and 1 mm (0.4-3.6) in AP view in the CC and lateral direction, respectively; and 1.3 mm (0.4-3.1) and 1.3 mm (0.4-3.4) in lateral view in the CC and AP direction, respectively. This motion was believed to be due to breathing. Conclusion: If swallowing can be suppressed during CT acquisition, the contribution to the internal margin for this motion is negligible. Breathing related motion is also believed to be of limited clinical relevance in current practice. However, it might become of importance in future, with further reduction of margins. </description>
    </item> <item>
      <title>Trismus in patients with oropharyngeal cancer: Relationship with dose in structures of mastication apparatus (Article)</title>
      <link>http://repub.eur.nl/res/pub/30086/</link>
      <pubDate>2008-05-01T00:00:00Z</pubDate>
      <description>Background. Our aim was to assess the correlation between the radiation therapy (RT) dose to the mastication apparatus and trismus of oropharyngeal cancer patients. Methods. Eighty-one patients treated with RT were analyzed. The masseter, pterygoid, and temporalis muscles and the coronoid and condyl were delineated on axial CT slices. The mean dose in these structures was correlated with outcome of quality of life questionnaires. Results. Fifty-six (88%) patients responded; 16% of the patients scored grade 3/4 on the Head &amp; Neck 35 "opening mouth" question. A significant correlation was observed between dose in masseter and pterygoid muscles and trismus (p = .02). Conclusion. Patients treated with brachytherapy received a lower dose in masticatory muscles. A steep dose-effect relationship between mean dose in masseter muscle and pterygoid muscles and the probability of having trismus complaints was observed; with every additional 10 Gy to the pterygoid muscle, an increase of the probability of trismus of 24% was observed. </description>
    </item> <item>
      <title>Quality of Life After Stereotactic Body Radiation Therapy for Primary and Metastatic Liver Tumors (Article)</title>
      <link>http://repub.eur.nl/res/pub/29715/</link>
      <pubDate>2008-04-01T00:00:00Z</pubDate>
      <description>Purpose: Stereotactic body radiation therapy (SBRT) provides a high local control rate for primary and metastatic liver tumors. The aim of this study is to assess the impact of this treatment on the patient's quality of life. This is the first report of quality of life associated with liver SBRT. Methods and Materials: From October 2002 to March 2007, a total of 28 patients not suitable for other local treatments and with Karnofsky performance status of at least 80% were entered in a Phase I-II study of SBRT for liver tumors. Quality of life was a secondary end point. Two generic quality of life instruments were investigated, EuroQol-5D (EQ-5D) and EuroQoL-Visual Analogue Scale (EQ-5D VAS), in addition to a disease-specific questionnaire, the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ C-30). Points of measurement were directly before and 1, 3, and 6 months after treatment. Mean scores and SDs were calculated. Statistical analysis was performed using paired-samples t-test and Student t-test. Results: The calculated EQ-5D index, EQ-5D VAS and QLQ C-30 global health status showed that mean quality of life of the patient group was not significantly influenced by treatment with SBRT; if anything, a tendency toward improvement was found. Conclusions: Stereotactic body radiation therapy combines a high local control rate, by delivering a high dose per fraction, with no significant change in quality of life. Multicenter studies including larger numbers of patients are recommended and under development. </description>
    </item> <item>
      <title>Local Anatomic Changes in Parotid and Submandibular Glands During Radiotherapy for Oropharynx Cancer and Correlation With Dose, Studied in Detail With Nonrigid Registration (Article)</title>
      <link>http://repub.eur.nl/res/pub/29652/</link>
      <pubDate>2008-03-01T00:00:00Z</pubDate>
      <description>Purpose: To quantify the anatomic changes caused by external beam radiotherapy in head-and-neck cancer patients in full three dimensions and to relate the local anatomic changes to the planned mean dose. Methods and Materials: A nonrigid registration method was adapted for RT image registration. The method was applied in 10 head-and-neck cancer patients, who each underwent a planning and a repeat computed tomography scan. Contoured structures (parotid, submandibular glands, and tumor) were registered in a nonrigid manner. The accuracy of the transformation was determined. The transformation results were used to summarize the anatomic changes on a local scale for the irradiated and spared glands. The volume reduction of the glands was related to the planned mean dose. Results: Transformation was accurate with a mean error of 0.6 ± 0.5 mm. The volume of all glands and the primary tumor decreased. The lateral regions of the irradiated parotid glands moved inward (average, 3 mm), and the medial regions tended to remain in the same position. The irradiated submandibular glands shrank and moved upward. The spared glands showed only a small deformation (∼1 mm in most regions). Overall, the primary tumors shrank. The volume loss of the parotid glands correlated significantly with the planned mean dose (p &lt;0.001). Conclusion: General shrinkage and deformation of irradiated glands was seen. The spared glands showed few changes. These changes were assessed by a nonrigid registration method, which effectively described the local changes occurring in the head-and-neck region after external beam radiotherapy. </description>
    </item> <item>
      <title>Time Dependence of Intrafraction Patient Motion Assessed by Repeat Stereoscopic Imaging (Article)</title>
      <link>http://repub.eur.nl/res/pub/29745/</link>
      <pubDate>2008-02-01T00:00:00Z</pubDate>
      <description>Purpose: To quantify intrafraction patient motion and its time dependence in immobilized intracranial and extracranial patients. The data can be used to optimize the intrafraction imaging frequency and consequent patient setup correction with an image guidance and tracking system, and to establish the required safety margins in the absence of such a system. Method and Materials: The intrafraction motion of 32 intracranial patients, immobilized with a thermoplastic mask, and 11 supine- and 14 prone-treated extracranial spine patients, immobilized with a vacuum bag, were analyzed. The motion was recorded by an X-ray, stereoscopic, image-guidance system. For each group, we calculated separately the systematic (overall mean and SD) and the random displacement as a function of elapsed intrafraction time. Results: The SD of the systematic intrafraction displacements increased linearly over time for all three patient groups. For intracranial-, supine-, and prone-treated patients, the SD increased to 0.8, 1.2, and 2.2 mm, respectively, in a period of 15 min. The random displacements for the prone-treated patients were significantly higher than for the other groups, namely 1.6 mm (1 SD), probably caused by respiratory motion. Conclusions: Despite the applied immobilization devices, patients drift away from their initial position during a treatment fraction. These drifts are in general small if compared with conventional treatment margins, but will significantly contribute to the margin for high-precision radiation treatments with treatment times of 15 min or longer. </description>
    </item> <item>
      <title>The HYPERcollar: A novel applicator for hyperthermia in the head and neck (Article)</title>
      <link>http://repub.eur.nl/res/pub/20653/</link>
      <pubDate>2007-11-01T00:00:00Z</pubDate>
      <description>The purpose of this work was to define all features, and show the potential, of the novel HYPERcollar applicator system for
hyperthermia treatments in the head and neck region. The HYPERcollar applicator consists of (1) an antenna ring, (2) a
waterbolus system and (3) a positioning system. The specific absorption rate (SAR) profile of this applicator was investigated by performing infra-red measurements in a cylindrical phantom. Mandatory patient-specific treatment planning was performed as an object lesson to a patient with a laryngeal tumour and an artificial lymph node metastasis. Comfort tests with healthy volunteers have revealed that the applicator provides sufficient comfort to maintain in treatment position for an hour: the standard hyperthermia treatment duration in our centre. By phantom measurements, we established that a central focus in the neck can be obtained, with 50% iso-SAR lengths of 3.5 cm in transversal directions (x/y) and 9–11 cm in the axial direction (z). Using treatment planning by detailed electromagnetic simulations, we showed that the SAR pattern can be optimised to enable simultaneous encompassing of a primary laryngeal tumour and a lymph node metastasis at the 25% iso-SAR level. This study shows that the applicator enables a good control, and sufficient possibilities for optimisation, of the SAR pattern. In an ongoing clinical feasibility study, we will investigate the possibilities of heating various target regions in the neck with this apparatus.</description>
    </item> <item>
      <title>Aesthetic and functional outcome following nasal reconstruction (Article)</title>
      <link>http://repub.eur.nl/res/pub/35190/</link>
      <pubDate>2007-10-01T00:00:00Z</pubDate>
      <description>BACKGROUND: Few reports on outcome of aesthetic nasal reconstruction exist. Therefore, subjective and objective aesthetic and functional outcome following nasal reconstruction was assessed. METHODS: Outcome was assessed in 38 consecutive patients treated for subtotal nasal defects using standardized semistructured interviews. Standardized physical examination forms and photographs were used. RESULTS: In six patients, one aesthetic subunit was involved; in 14, two; and in 18, three or more. Defects were classified as skin only (13 percent), skin/cartilage (21 percent), and full thickness (66 percent). Some defects (32 percent) involved adjacent aesthetic units. Inner lining was reconstructed with local mucosa or turnover skin flaps. Support was provided with regional cartilage grafts and/or composite septal flaps. Skin defects were reconstructed with forehead, nasolabial, cheek advancement, Abbé, facial artery perforator, or free radial forearm flaps. Nasal reconstructions required 116 procedures. Thirty-three patients participated in the follow-up study. Mucosal crusting was noted in 36 percent, passage difficulties in 31 percent, and worse olfaction in 16 percent. Phonation was unchanged. Eighty-one percent were very satisfied with nasal function. Flap color match was moderate to good in 97 percent; hair growth occurred in 61 percent. At critical inspection, a thicker flap (58 percent), smaller ostium nasi (77 percent), thicker alar rim (86 percent), and minor alar rim retraction (46 percent) were noted. Seventy-nine percent were very satisfied with total nasal appearance. CONCLUSION: Although objective functional and aesthetic outcome following nasal reconstruction sometimes shows impairment compared with the normal situation, it gives high subjective patient satisfaction with function and aesthetics. </description>
    </item> <item>
      <title>Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: A dose-effect relationship (Article)</title>
      <link>http://repub.eur.nl/res/pub/35722/</link>
      <pubDate>2007-10-01T00:00:00Z</pubDate>
      <description>Purpose/Objective: To assess the relationship between the radiation therapy (RT) dose received by the muscular components of the swallowing (sw) apparatus and - dysphagia related - quality of life (QoL) in oropharyngeal cancer. Materials/Methods: Between 2000 and 2005, 81 patients with SCC of the oropharynx were treated by 3DCRT or IMRT, with or without concomitant chemotherapy (CHT); 43 out of these 81 patients were boosted by brachytherapy (BT). Charts of 81 patients were reviewed with regard to late dysphagia complaints; 23% experienced severe dysphagia. Seventeen patients expired. Fifty-six out of 64 (88%) responded to quality of life (QoL) questionnaires; that is, the Performance Status Scales of List, EORTC H&amp;N35, and the M.D. Anderson Dysphagia Inventory. The superior (scm), middle (mcm), and inferior constrictor muscle (icm), the cricopharyngeus muscle and the inlet of the esophagus, are considered of paramount importance for swallowing. The mean dose was calculated in the muscular structures. Univariate analysis and multivariate analysis were performed using the proportional odds model. Results: Mean follow-up was 18 months (range 2-34) for IMRT, and 46 months for 3DCRT (range 2-72). At 3-years, a LRC of 84%, DFS of 78% and OS of 77% were observed. A significant correlation was observed between the mean dose in the scm and mcm, and severe dysphagia complaints (univariate analysis). A steep dose-effect relationship, with an increase of the probability of dysphagia of 19% with every additional 10 Gy, was established. In the multivariate analysis, BT (dose) was the only significant factor. Conclusion: A dose-effect relationship between dose and swallowing complaints was observed. One way to improve the QoL is to constrain the dose to be received by the swallowing muscles. </description>
    </item> <item>
      <title>Can IMRT or Brachytherapy Reduce Dysphagia Associated With Chemoradiotherapy of Head and Neck Cancer? The Michigan and Rotterdam Experiences (Article)</title>
      <link>http://repub.eur.nl/res/pub/36023/</link>
      <pubDate>2007-10-01T00:00:00Z</pubDate>
      <description>Purpose: Dysphagia is a major late complication of intensive chemoradiotherapy of head and neck cancer. The initial clinical results of intensity-modulated radiotherapy (IMRT), or brachytherapy, planned specifically to reduce dysphagia are presented. Patients and Methods: Previous research at Michigan University has suggested that the pharyngeal constrictors and glottic and supraglottic larynx are likely structures whose damage by chemo-RT causes dysphagia and aspiration. In a prospective Michigan trial, 36 patients with oropharyngeal (n = 31) or nasopharyngeal (n = 5) cancer underwent chemo-IMRT. IMRT cost functions included sparing noninvolved pharyngeal constrictors and the glottic and supraglottic larynx. After a review of published studies, the retropharyngeal nodes at risk were defined as the lateral, but not the medial, retropharyngeal nodes, which facilitated sparing of the swallowing structures. In Rotterdam, 77 patients with oropharyngeal cancer were treated with IMRT, three dimensional RT, or conventional RT; also one-half received brachytherapy. The dysphagia endpoints included videofluoroscopy and observer-assessed scores at Michigan and patient-reported quality-of-life instruments in both studies. Results: In both studies, the doses to the upper and middle constrictors correlated highly with the dysphagia endpoints. In addition, doses to the glottic and supraglottic larynx were significant in the Michigan series. In the Rotterdam series, brachytherapy (which reduced the doses to the swallowing structures) was the only significant factor on multivariate analysis. Conclusion: The dose-response relationships for the swallowing structures found in these studies suggest that reducing their doses, using either IMRT aimed at their sparing, or brachytherapy, might achieve clinical gains in dysphagia. </description>
    </item> <item>
      <title>Performance of a dedicated light delivery and dosimetry device for photodynamic therapy of nasopharyngeal carcinoma: Phantom and volunteer experiments (Article)</title>
      <link>http://repub.eur.nl/res/pub/35733/</link>
      <pubDate>2007-09-01T00:00:00Z</pubDate>
      <description>The objective of this study was to develop a light delivery and measurement device for photodynamic therapy (PDT) in the nasopharyngeal cavity, which achieves a homogeneous and reproducible fiuence rate distribution to a target area and provides proper shielding of predefined risk areas. Materials and Methods: A flexible silicone applicator was developed, incorporating light delivery and dosimetry fibers. The applicator can be inserted through the mouth and fixed in the nasopharyngeal cavity. Tissue optical phantoms were prepared on the basis of optical properties measured in vivo using diffuse reflectance spectroscopy (DRS). The fluence rate over the length of the applicator surface was measured in air, in tissue optical phantoms and in five healthy volunteers. Results: The fluence rate distribution over the applicator surface in air and tissue optical phantom was found to be more homogeneous (SD/mean 3.8% and 18.3%, respectively) than the fluence rate distribution in five volunteers (SD/mean ranging from 19% up to 52%). The maximum observed fiuence rate build-up in the nasopharynx varied between subjects and ranged from a factor of 4.1-6.9. Shielding of the risk area such as the soft palate and tongue was effective. Conclusions: In air and in tissue optical phantoms the fluence rate distribution of the device was highly homogeneous. The observed inter-subject and intra-subject variations in fluence rate in healthy volunteers originated from differences in optical properties and nasopharyngeal geometry. Light delivery based on a single tissue surface measurement will not be adequate. In situ dosimetric measurements are required to determine the light fluence delivered to a geometrically complex site such as the nasopharynx. These observations should be taken in consideration when developing light applicators for PDT of the nasopharynx and other non-uniform surfaces. </description>
    </item> <item>
      <title>On heating head and neck tumours using the novel clinical em applicator: the HYPERcollar (Article)</title>
      <link>http://repub.eur.nl/res/pub/20654/</link>
      <pubDate>2007-05-01T00:00:00Z</pubDate>
      <description>Abstract
Purpose: Definition of all features and the potential of the novel HYPERcollar applicator system for hyperthermia treatments in the head and neck (H&amp;N) region.
Methods and Materials: The HYPERcollar applicator consists of 1) an antenna ring, 2) a waterbolus system and 3) a positioning system. The specific absorption rate (SAR) profile of this applicator is investigated by performing infra-red (IR) measurements in a cylindrical phantom. Mandatory patient-specific treatment planning is performed as an object lesson to a patient with a laryngeal tumour and an artificial lymph node metastasis.
Results: The comfort tests with healthy volunteers have revealed that the applicator provides su±cient comfort to maintain in treatment position for an hour: in our center the standard hyperthermia treatment duration. We further established that a central focus in the neck can be obtained, with 50% iso-SAR lengths of 3.5cm in transversal directions and 9-11cm in the axial direction (z). Using treatment planning by detailed electromagnetic simulations, we showed that the SAR pattern can be optimized to enable simultaneous encompassing a primary laryngeal tumour and a lymph node metastasis at the 25% iso-SAR level.
Conclusions: A site-specific H&amp;N applicator was designed that enables good control and sufficient possibilities for optimizing the SAR pattern. In an ongoing clinical feasibility study we will investigate the possibilities of heating various target regions in the neck with this apparatus.</description>
    </item> <item>
      <title>Quantification of Trade-Off Between Parotid Gland Sparing and Planning Target Volume Underdosages in Clinically Node-Negative Head-and-Neck Intensity-Modulated Radiotherapy (Article)</title>
      <link>http://repub.eur.nl/res/pub/36096/</link>
      <pubDate>2007-05-01T00:00:00Z</pubDate>
      <description>Purpose: To quantify the trade-off between parotid gland sparing and planning target volume (PTV) underdosages for head-and-neck intensity-modulated radiotherapy. Methods and Materials: A planning study was performed for 4 patients with either soft palate or tonsil tumors treated with external radiotherapy up to 46 Gy. The trade-off between underdosages in the PTV and sparing of the parotid glands was investigated by systematically varying the optimization objectives for the inverse planning. A new way of presenting dose-volume information allows easy detection of small PTV subvolumes with underdosages that cannot be assessed in conventional cumulative dose-volume histograms. A simple radiobiological model to estimate the control probability for an electively irradiated neck level was developed. Results: The average dose to the parotid glands can decrease by &gt;10 Gy by allowing the PTV to be underdosed in such a way that the radiobiological model predicts a decrease in subclinical disease control probability of (typically) 1% to a few percent. Conclusion: The trade-off between parotid gland sparing and underdosages in the PTV has been quantified by the use of an alternative method to present dose-volume information and by the use of a radiobiological model to predict subclinical disease control probability. </description>
    </item> <item>
      <title>Target Coverage in Image-Guided Stereotactic Body Radiotherapy of Liver Tumors (Article)</title>
      <link>http://repub.eur.nl/res/pub/36099/</link>
      <pubDate>2007-05-01T00:00:00Z</pubDate>
      <description>Purpose: To determine the effect of image-guided procedures (with computed tomography [CT] and electronic portal images before each treatment fraction) on target coverage in stereotactic body radiotherapy for liver patients using a stereotactic body frame (SBF) and abdominal compression. CT guidance was used to correct for day-to-day variations in the tumor's mean position in the SBF. Methods and Materials: By retrospectively evaluating 57 treatment sessions, tumor coverage, as obtained with the clinically applied CT-guided protocol, was compared with that of alternative procedures. The internal target volume-plus (ITV+) was introduced to explicitly include uncertainties in tumor delineations resulting from CT-imaging artifacts caused by residual respiratory motion. Tumor coverage was defined as the volume overlap of the ITV+, derived from a tumor delineated in a treatment CT scan, and the planning target volume. Patient stability in the SBF, after acquisition of the treatment CT scan, was evaluated by measuring the displacement of the bony anatomy in the electronic portal images relative to CT. Results: Application of our clinical protocol (with setup corrections following from manual measurements of the distances between the contours of the planning target volume and the daily clinical target volume in three orthogonal planes, multiple two-dimensional) increased the frequency of nearly full (≥99%) ITV+coverage to 77% compared with 63% without setup correction. An automated three-dimensional method further improved the frequency to 96%. Patient displacements in the SBF were generally small (≤2 mm, 1 standard deviation), but large craniocaudal displacements (maximal 7.2 mm) were occasionally observed. Conclusion: Daily, CT-assisted patient setup may substantially improve tumor coverage, especially with the automated three-dimensional procedure. In the present treatment design, patient stability in the SBF should be verified with portal imaging. </description>
    </item> <item>
      <title>Longitudinal Changes in Quality of Life and Treatment Costs in Long-term Survivors of Tumors of the Oropharynx Treated with Brachytherapy or Surgery (Proceedings)</title>
      <link>http://repub.eur.nl/res/pub/23526/</link>
      <pubDate>2005-10-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Long term outcome after intracoronary beta radiation therapy (Article)</title>
      <link>http://repub.eur.nl/res/pub/8356/</link>
      <pubDate>2005-01-01T00:00:00Z</pubDate>
      <description>OBJECTIVES: To determine the long term outcome after intracoronary beta radiation therapy (IRT). SETTING: Tertiary referral centre. METHODS: The rate of major adverse cardiac events (MACE) was retrospectively determined in 301 consecutive patients who were treated with IRT. MACE was defined as death, myocardial infarction, or any reintervention. Long term clinical outcome was obtained from an electronic database of hospital records and from questionnaires to the patients and referring physicians. Long term survival status was assessed by written inquiries to the municipal civil registries. RESULTS: The mean (SD) follow up was 3.6 (1.2) years. The cumulative incidence of MACE at six months was 19.1%, at one year 36.4%, and at four years 58.3%. The target lesion revascularisation (TLR) rate at six months was 12.9%, at one year 28.3%, and at four years 50.4%. From multivariate analysis, dose &lt; 18 Gy was the most significant predictor of TLR. At four years the cumulative incidence of death was 3.8%, of myocardial infarction 13.4%, and of coronary artery bypass surgery 11.3%. Total vessel occlusion was documented in 12.3% of the patients. CONCLUSIONS: In the long term follow up of patients after IRT, there are increased adverse cardiac events beyond the first six months.</description>
    </item> <item>
      <title>A biplane angiographic study on cardiac motion of coronary artery stents: options to minimize the target volume for high-precision external beam radiotherapy of coronary artery in-stent restenosis. (Article)</title>
      <link>http://repub.eur.nl/res/pub/4695/</link>
      <pubDate>2004-01-01T00:00:00Z</pubDate>
      <description>PURPOSE: High-precision external beam radiotherapy (EBRT) has been suggested as a potential alternative to endovascular brachytherapy for the treatment of coronary artery in-stent restenosis. The purpose of our study was to investigate and compare different options to define a smallest feasible target volume. METHODS AND MATERIALS: The cardiac motion of 17 coronary artery stents in 17 patients was studied by use of biplane conventional angiography, recorded during breath-hold. Each stent was reconstructed in three dimensions by use of biplane sets of frames covering an entire cardiac cycle. The volume traversed by the stent during the entire or part of the cardiac cycle was determined. Four options to define the stent-traversed volume (STV) as a target for high-precision EBRT were investigated. RESULTS: The mean STV during the entire cardiac cycle was 3.5 cm3; the STV represented less than 1% of the heart volume in all patients. The STV during the diastolic and systolic phase resulted in a mean reduction of 26.6% and 29.1%, respectively, compared with the STV during the entire cardiac cycle. The smallest STV, measured during a 160-ms interval within the cardiac cycle, resulted in a mean maximal reduction of 75.9% compared with the STV during the entire cardiac cycle. CONCLUSIONS: The STV during the entire cardiac cycle represents a small potential target volume for high-precision EBRT. A significant reduction of this target volume is possible in case of definition during a selected interval within the cardiac cycle.</description>
    </item> <item>
      <title>Routine intracoronary beta-irradiation. Acute and one year outcome in patients at high risk for recurrence of stenosis (Article)</title>
      <link>http://repub.eur.nl/res/pub/9929/</link>
      <pubDate>2002-07-01T00:00:00Z</pubDate>
      <description>AIMS: Intracoronary radiation is a promising therapy potentially reducing restenosis following catheter-based interventions. Currently, only limited data on this treatment are available. The feasibility and outcome in daily routine practice, however, is unknown. METHODS AND RESULTS: In 100 consecutive patients, intracoronary beta-radiation was performed with a (90)Strontium system (Novoste Beta-Cathtrade mark) following angioplasty. Predominantly complex (73% type B2 and C) and long lesions (length 24.3+/-15.3 mm) were included (37% de novo, 19% restenotic and 44% in-stent restenotic lesions). Radiation success was 100%. Mean prescribed dose was 19.8+/-2.5 Gy. A pullback procedure was performed in 19% lesions. Geographic miss occurred in 8% lesions. Periprocedural thrombus formation occurred in four lesions, dissection in nine lesions. During hospital stay, no death, acute myocardial infarction, or repeat revascularization was observed. Major adverse cardiac events occurred predominantly between 6 and 12 months after the index procedure with major adverse cardiac event-free survival of 66% at 12 months (one death, 10 Q-wave myocardial infarctions, 23 target vessel revascularizations; ranked for worst event). CONCLUSION: Routine catheter-based intracoronary beta-radiation therapy after angioplasty is safe and feasible with a high acute procedural success. The clinical 1-year follow-up showed delayed occurrence of major adverse cardiac events between 6 and 12 months after the index procedure</description>
    </item> <item>
      <title>Coronary stent traversed volume during the cardiac cycle defined as a target for high-precision radiotherapy by using biplane angiograms. (Article)</title>
      <link>http://repub.eur.nl/res/pub/4793/</link>
      <pubDate>2002-06-24T00:00:00Z</pubDate>
      <description>Three-dimensional reconstructions of 19 coronary artery stents from biplane angiograms were used for measurement of the volume through which the stents traversed during the cardiac cycle. This volume, less than 0.8% of the whole heart volume in all patients, represents a target volume for high-precision radiotherapy to treat coronary artery in-stent restenosis.</description>
    </item> <item>
      <title>Initial observation regarding changes in vessel dimensions after balloon angioplasty and stenting followed by catheter-based beta-radiation. Is stenting necessary in the setting of catheter-based radiotherapy? (Article)</title>
      <link>http://repub.eur.nl/res/pub/13059/</link>
      <pubDate>2002-04-01T00:00:00Z</pubDate>
      <description>AIMS: We sought to compare the effect of intracoronary beta-radiation on the vessel dimensions in de novo lesions using three-dimensional intravascular ultrasound quantification after balloon angioplasty and stenting. METHODS AND RESULTS: Forty patients (44 vessels; 28 balloon angioplasty and 16 stenting) treated with catheter-based beta-radiation and 18 non-irradiated control patients (18 vessels; 10 balloon angioplasty and 8 stenting) were investigated by means of three-dimensional volumetric intravascular ultrasound analysis post-procedure and at 6-8 months follow-up. Total vessel (EEM) volume enlarged after both balloon angioplasty and stenting (+37 mm(3) vs +42 mm(3), P=ns), but vessel wall volume (plaque plus media) also increased similarly (+33 mm(3) vs +49 mm(3), P=ns) in the irradiated patients. Lumen volume remained unchanged in both groups (+3 mm(3) vs -7 mm(3), P=ns). In the stent-covered segments, neointima at follow-up was significantly smaller in the irradiated group than the control group (8 mm(3) vs 27 mm(3), P=0.001, respectively), but the total amount of tissue growth was similar in both groups (33 mm(3) vs 29 mm(3), P=ns). CONCLUSIONS: Intracoronary beta-radiation induces vessel enlargement after balloon angioplasty and/or stenting, accommodating tissue growth. Additional stenting may not play an important role in the prevention of constrictive remodelling in the setting of catheter-based intracoronary beta-radiotherapy.</description>
    </item> <item>
      <title>Angiographical follow-up after radioactive "Cold Ends" stent implantation: a multicenter trial. (Article)</title>
      <link>http://repub.eur.nl/res/pub/9837/</link>
      <pubDate>2002-02-05T00:00:00Z</pubDate>
      <description>BACKGROUND: Radioactive stents with an activity of 0.75 to 12 microCi have shown &gt;40% edge restenosis due to neointimal hyperplasia and negative remodeling. This trial evaluated whether radioactive Cold Ends stents might resolve edge restenosis by preventing remodeling at the injured extremities. METHODS AND RESULTS: The 25-mm long (15-mm radioactive center and 5-mm nonradioactive ends) Cold Ends stents had an activity of 3 to 12 microCi at implantation. Forty-three stents were implanted in 43 patients with de novo native coronary artery disease. Two procedural, 1 subacute, and 1 late stent thrombosis occurred. A restenosis rate of 22% was observed with a shift of the restenosis, usually occurring at the stent edges of radioactive stents, into the Cold Ends stents. The most severe restenosis occurred at the transition zone from radioactive to nonradioactive segments, a region located in dose fall-off. CONCLUSION: Cold Ends stents did not resolve edge restenosis.</description>
    </item> <item>
      <title>Definition of a moving gross target volume for stereotactic radiation therapy of stented coronary arteries. (Article)</title>
      <link>http://repub.eur.nl/res/pub/4800/</link>
      <pubDate>2002-02-01T00:00:00Z</pubDate>
      <description>PURPOSE: To measure the effect of cardiac motion on coronary artery stent position during the cardiac cycle as a first step toward exploring the feasibility of stereotactic external beam radiation therapy targeted at restenotic stented coronary arteries. METHODS AND MATERIALS: The three-dimensional (3D) position of eight coronary artery stents in 8 patients immobilized in a stereotactic body frame was studied noninvasively by single-breathhold ECG-gated multislice spiral computed tomography (MSCT) during 10 retrospectively selected phases, equally distributed throughout the R-R interval of consecutive cardiac cycles. The volume encompassing all measured 3D positions of the stent was measured. RESULTS: Stent volumes measured by MSCT closely agreed with measurements by quantitative coronary angiography (r &gt; 0.99). The mean of the maximum 3D stent center of mass displacement between any two phases during the cardiac cycle for all eight coronary arteries was 7.5 mm (range 3.3-20.5 mm) in the lateral direction, 8.6 mm (range 2.7-21.6 mm) in the ventrodorsal direction, and 8.2 mm (range 2.5-19.7 mm) in the craniocaudal direction. As was anticipated, the volume encompassing all measured 3D positions of the stent represented only a fraction of the whole heart volume in all patients, i.e., less than 0.6%. CONCLUSIONS: ECG-gated MSCT allowed the measurement of the volume encompassing multiphase 3D positions of coronary artery stents during the cardiac cycle. This volume, a measure of the cardiac motion effect on coronary artery stent position during the cardiac cycle, represents a moving gross target for stereotactic external beam radiation therapy.</description>
    </item> <item>
      <title>Comparison of different methods to define a target volume for external beam radiation therapy of restenotic coronary arteries. (Article)</title>
      <link>http://repub.eur.nl/res/pub/4816/</link>
      <pubDate>2001-12-01T00:00:00Z</pubDate>
      <description>Purpose: Different methods have been described to define a target volume for the treatment of restenotic (stented) coronary arteries by external beam radiation therapy (EBRT). The purpose of this study was to explore two methods to define a target for such therapy, and to compare these with previously investigated methods. Materials and methods: The 3-D position of a stent throughout the cardiac cycle in the three major epicardial coronary arteries was measured in three patients by single-breathhold multislice spiral CT and breathhold biplane conventional X-ray angiography, both indexed in time with the ECG. The volume through which the stent traversed (STV) during the cardiac cycle was determined by use of displacement measurements. Results: For multislice CT and biplane angiography, respectively, the mean STV was 1.23 cm3 (range 0.65-2.22 cm3) and 2.81 cm3 (range 1.60-4.99 cm3). The STV represented only a fraction of the whole heart volume in all patients, that is, equal to or less than 0.4%. Conclusions: Multislice CT and biplane angiography allowed the measurement of a relatively small potential target, that is the STV, for EBRT of restenotic stented coronary arteries. Both studied imaging modalities are instrumental for targeting the STV by highly conformal radiation therapy in case of restenotic stented coronary arteries.</description>
    </item> <item>
      <title>The pattern of restenosis and vascular remodelling after cold-end radioactive stent implantation. (Article)</title>
      <link>http://repub.eur.nl/res/pub/4825/</link>
      <pubDate>2001-08-22T00:00:00Z</pubDate>
      <description>Background Edge restenosis is a major problem after radioactive stenting. The cold-end stent has a radioactive mid-segment (15·9mm) and non-radioactive proximal and distal 5·7mm segments. Conceptually this may negate the impact of negative vascular remodelling at the edge of the radiation.

Method and Results ECG-gated intravascular ultrasound with three-dimensional reconstruction was performed post-stent implantation and at the 6-month follow-up to assess restenosis within the margins of the stent and at the stent edges in 16 patients. Angiographic restenosis was witnessed in four patients, all in the proximal in-stent position. By intravascular ultrasound in-stent neointimal hyperplasia, with a &gt;50% stented cross-sectional area, was seen in eight patients. This was witnessed proximally (n=2), distally (n=2) and in both segments (n=4). Echolucent tissue, dubbed the ‘black hole’ was seen as a significant component of neointimal hyperplasia in six out of the eight cases of restenosis. Neointimal hyperplasia was inhibited in the area of radiation: Δ neointimal hyperplasia=3·72mm3(8·6%); in-stent at the edges of radiation proximally and distally Δ neointimal hyperplasia was 7·9mm3(19·0%) and 11·4mm3(25·6%), respectively (P=0·017). At the stent edges there was no significant change in lumen volume.

Conclusions Cold-end stenting results in increased neointimal hyperplasia in in-stent non-radioactive segments.</description>
    </item> <item>
      <title>Clinical and angiographical follow-up after implantation of a 6--12 microCi radioactive stent in patients with coronary artery disease. (Article)</title>
      <link>http://repub.eur.nl/res/pub/12923/</link>
      <pubDate>2001-07-19T00:00:00Z</pubDate>
      <description>AIMS: This study is the contribution by the Thoraxcenter, Rotterdam, to the European(32)P Dose Response Trial, a non-randomized multicentre trial to evaluate the safety and efficacy of the radioactive Isostent in patients with single coronary artery disease. METHODS AND RESULTS: The radioactivity of the stent at implantation was 6--12 microCi. All patients received aspirin indefinitely and either ticlopidine or clopidogrel for 3 months. Quantitative coronary angiography measurements of both the stent area and the target lesion (stent area and up to 5 mm proximal and distal to the stent edges) were performed pre- and post-procedure and at the 5-month follow-up. Forty-two radioactive stents were implanted in 40 patients. Treated vessels were the left anterior descending coronary artery (n=20), right coronary artery (n=10) or left circumflex artery (n=10). Eight patients received additional non-radioactive stents. Lesion length measured 10+/-3 mm with a reference diameter of 3.07+/-0.69 mm. Minimal lumen diameter increased from 0.98+/-0.53 mm pre-procedure to 2.29+/-0.52 mm (target lesion) and 2.57+/-0.44 mm (stent area) post-procedure. There was one procedural non-Q wave myocardial infarction, due to transient thrombotic closure. Thirty-six patients returned for angiographical follow-up. Two patients had a total occlusion proximal to the radioactive stent. Of the patent vessels, none had in-stent restenosis. Edge restenosis was observed in 44%, occurring predominantly at the proximal edge. Target lesion revascularization was performed in 10 patients and target vessel revascularization in one patient. No additional clinical end-points occurred during follow-up. The minimal lumen diameter at follow-up averaged 1.66+/-0.71 mm (target lesion) and 2.12+/-0.72 (stent area); therefore late loss was 0.63+/-0.69 (target lesion) and 0.46+/-0.76 (stent area), resulting in a late loss index of 0.65+/-1.15 (target lesion) and 0.30+/-0.53 (stent area). CONCLUSION: These results indicate that the use of radioactive stents is safe and feasible, however, the high incidence of edge restenosis makes this technique currently clinically non-applicable.</description>
    </item> <item>
      <title>Radioactive stents delay but do not prevent in-stent neointimal hyperplasia (Article)</title>
      <link>http://repub.eur.nl/res/pub/9562/</link>
      <pubDate>2001-01-01T00:00:00Z</pubDate>
      <description>BACKGROUND: Restenosis after conventional stenting is almost exclusively caused by neointimal hyperplasia. Beta-particle-emitting radioactive stents decrease in-stent neointimal hyperplasia at 6-month follow-up. The purpose of this study was to evaluate the 1-year outcome of (32)P radioactive stents with an initial activity of 6 to 12 microCi using serial quantitative coronary angiography and volumetric ECG-gated 3D intravascular ultrasound (IVUS). METHODS AND RESULTS: Of 40 patients undergoing initial stent implantation, 26 were event-free after the 6-month follow-up period and 22 underwent repeat catheterization and IVUS at 1 year; they comprised half of the study population. Significant luminal deterioration was observed within the stents between 6 months and 1 year, as evidenced by a decrease in the angiographic minimum lumen diameter (-0.43+/-0.56 mm; P:=0.028) and in the mean lumen diameter in the stent (-0.55+/-0. 63 mm; P:=0.001); a significant increase in in-stent neointimal hyperplasia by IVUS (18.16+/-12.59 mm(3) at 6 months to 27.75+/-11. 99 mm(3) at 1 year; P:=0.001) was also observed. Target vessel revascularization was performed in 5 patients (23%). No patient experienced late occlusion, myocardial infarction, or death. By 1 year, 21 of the initial 40 patients (65%) remained event-free. CONCLUSIONS: Neointimal proliferation is delayed rather than prevented by radioactive stent implantation. Clinical outcome 1 year after the implantation of stents with an initial activity of 6 to 12 microCi is not favorable when compared with conventional stenting.</description>
    </item> <item>
      <title>"Edge Effect" of 32P Radioactive Stents Is Caused by the Combination of Chronic Stent Injury and Radioactive Dose Falloff (Article)</title>
      <link>http://repub.eur.nl/res/pub/9781/</link>
      <pubDate>2001-01-01T00:00:00Z</pubDate>
      <description>BACKGROUND: Radioactive stents have been reported to reduce in-stent neointimal thickening. An unexpected increase in neointimal response was observed, however, at the stent-to-artery transitions, the so-called "edge effect." To investigate the factors involved in this edge effect, we studied stents with 1 radioactive half and 1 regular nonradioactive half, thereby creating a midstent radioactive dose-falloff zone next to a nonradioactive stent-artery transition at one side and a radioactive stent-artery transition at the other side. METHODS AND RESULTS: Half-radioactive stents (n=20) and nonradioactive control stents (n=10) were implanted in the coronary arteries of Yucatan micropigs. Animals received aspirin and clopidogrel as antithrombotics. After 4 weeks, a significant midstent stenosis was observed by angiography in the half-radioactive stents. Two animals died suddenly because of coronary occlusion at this mid zone at 8 and 10 weeks. At 12-week follow-up angiography, intravascular ultrasound and histomorphometry showed a significant neointimal thickening at the midstent dose-falloff zone of the half-radioactive stents, but not at the stent-to-artery transitions at both extremities. Such a midstent response (mean angiographic late loss 1.0 mm) was not observed in the nonradioactive stents (mean loss 0.4 to 0.6 mm; P&lt; 0.01). CONCLUSIONS: The edge effect of high-dose radioactive stents in porcine coronary arteries is associated with the combination of stent injury and radioactive dose falloff.</description>
    </item> <item>
      <title>Relationship between tensile stress and plaque growth after balloon angioplasty treated with and without intracoronary beta-brachytherapy. (Article)</title>
      <link>http://repub.eur.nl/res/pub/12895/</link>
      <pubDate>2000-12-01T00:00:00Z</pubDate>
      <description>AIMS: We investigated the influence of tensile stress on plaque growth after balloon angioplasty with and without beta-radiation therapy. METHODS AND RESULTS: Thirty-one consecutive patients successfully treated with balloon angioplasty were analysed qualitatively and quantitatively by means of an ECG-gated three-dimensional intravascular ultrasound post-procedure and at follow-up. Eighteen patients were irradiated with catheter-based beta-radiation ((90)Sr/(90)Y source) and 13 were not (control). Studied segments were divided into 2 mm subsegments. Thus 184 irradiated and 111 non-irradiated subsegments were included. Tensile stress was calculated according to Laplace's law. The radiation dose was calculated by means of dose-volume histograms. Plaque growth was positively correlated to tensile stress in both the radiation and control groups (r=0.374, P=0.0001 and r=0.305, P=0.001). Low-dose subsegments (&lt;6 Gy) had a significant correlation (r=0.410, P=0.0001) whereas no correlation was observed in the effective-dose subsegments (&gt; or = 6 Gy). Multivariate analysis identified tensile stress as the only independent predictor of plaque increase in non-irradiated subsegments, whereas actual dose and plaque morphology were stronger predictors in irradiated subsegments. CONCLUSION: The results of this study suggest that plaque growth is related to tensile stress after balloon angioplasty. Intracoronary brachytherapy may alter the biophysical process on plaque growth when the prescribed dose is effectively delivered.</description>
    </item> <item>
      <title>Positive Geometric Vascular Remodeling Is Seen After Catheter-Based Radiation Followed by Conventional Stent Implantation but Not After Radioactive Stent Implantation (Article)</title>
      <link>http://repub.eur.nl/res/pub/4868/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>Background—Recent reports demonstrate that intracoronary radiation affects not only neointimal formation but also vascular remodeling. Radioactive stents and catheter-based techniques deliver radiation in different ways, suggesting that different patterns of remodeling after each technique may be expected.

Methods and Results—We analyzed remodeling in 18 patients after conventional stent implantation, 16 patients after low-activity radioactive stent implantation, 16 patients after higher activity radioactive stent implantation, and, finally, 17 patients who underwent catheter-based radiation followed by conventional stent implantation. Intravascular ultrasound with 3D reconstruction was used after stent implantation and at the 6-month follow-up to assess remodeling within the stent margins and at its edges. Preprocedural characteristics were similar between groups. In-stent neointimal hyperplasia (NIH) was inhibited by high-activity radioactive stent implantation (NIH 9.0 mm3) and by catheter-based radiation followed by conventional stent implantation (NIH 6.9 mm3) compared with low-activity radioactive stent implantation (NIH 21.2 mm3) and conventional stent implantation (NIH 20.8 mm3) (P=0.008). No difference in plaque or total vessel volume was seen behind the stent in the conventional, low-activity, or high-activity stent implantation groups. However, significant increases in plaque behind the stent (15%) and in total vessel volume (8%) were seen in the group that underwent catheter-based radiation followed by conventional stent implantation. All 4 groups demonstrated significant late lumen loss at the stent edges; however, edge restenosis was seen only in the group subjected to high-activity stent implantation and appeared to be due to an increase in plaque and, to a lesser degree, to negative remodeling.

Conclusions—Distinct differences in the patterns of remodeling exist between conventional, radioactive, and catheter-based radiotherapy with stenting.</description>
    </item> <item>
      <title>Residual Plaque Burden, Delivered Dose, and Tissue Composition Predict 6-Month Outcome After Balloon Angioplasty and Beta-Radiation Therapy (Article)</title>
      <link>http://repub.eur.nl/res/pub/4888/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>Background—Inhomogeneity of dose distribution and anatomic aspects of the atherosclerotic plaque may influence the outcome of irradiated lesions after balloon angioplasty (BA). We evaluated the influence of delivered dose and morphological characteristics of coronary stenoses treated with ß-radiation after BA.

Methods and Results—Eighteen consecutive patients treated according to the Beta Energy Restenosis Trial 1.5 were included in the study. The site of angioplasty was irradiated with the use of a ß-emitting 90Sr/90Y source. With the side branches used as anatomic landmarks, the irradiated area was identified and volumetric assessment was performed by 3D intracoronary ultrasound imaging after treatment and at 6 months. The type of tissue, the presence of dissection, and the vessel volumes were assessed every 2 mm within the irradiated area. The minimal dose absorbed by 90% of the adventitial volume (Dv90Adv) was calculated in each 2-mm segment. Diffuse calcified subsegments and those containing side branches were excluded. Two hundred six coronary subsegments were studied. Of those, 55 were defined as soft, 129 as hard, and 22 as normal/intimal thickening. Plaque volume showed less increase in hard segments as compared with soft and normal/intimal thickening segments (P&lt;0.0001). Dv90Adv was associated with plaque volume at follow-up after a polynomial equation with linear and nonlinear components (r=0.71; P=0.0001). The multivariate regression analysis identified the independent predictors of the plaque volume at follow-up: plaque volume after treatment, Dv90Adv, and type of plaque.

Conclusions—Residual plaque burden, delivered dose, and tissue composition play a fundamental role in the volumetric outcome at 6-month follow-up after ß-radiation therapy and BA.</description>
    </item> <item>
      <title>Geographic Miss (Article)</title>
      <link>http://repub.eur.nl/res/pub/4889/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>Background—A recognized limitation of endovascular ß-radiation therapy is the development of new stenosis at the edges of the irradiated area. The combination of injury and low-dose radiation may be the precursor of this phenomenon. We translated the radio-oncological concept of "geographic miss" to define cases in which the radiation source did not fully cover the injured area. The aims of the study were to determine the incidence and causes of geographic miss and evaluate the impact of this inadequate treatment on the outcome of patients treated with intracoronary ß-radiation.

Methods and Results—We analyzed 50 consecutive patients treated with ß-radiation after percutaneous coronary intervention. The prescribed dose ranged between 12 and 20 Gy at 2 mm from the source axis. By means of quantitative coronary angiography, the irradiated segment (IRS) and both edges were studied before and after intervention and at 6-month follow-up. Edges that were injured during the procedure constituted the geographic miss edges. Twenty-two edges were injured during the intervention, mainly because of procedural complications that extended the treatment beyond the margins of the IRS. Late loss was significantly higher in geographic miss edges than in IRSs and uninjured edges (0.84±0.6 versus 0.15±0.4 and 0.09±0.4 mm, respectively; P&lt;0.0001). Similarly, restenosis rate was significantly higher in the injured edges (10% within IRS, 40.9% in geographic miss edges, and 1.9% in uninjured edges; P&lt;0.001).

Conclusions—These data support the hypothesis that the combination of injury and low-dose ß-radiation induces deleterious outcome.</description>
    </item> <item>
      <title>Outcome from balloon induced coronary artery dissection after intracoronary beta radiation (Article)</title>
      <link>http://repub.eur.nl/res/pub/8353/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>OBJECTIVE: To evaluate the healing of balloon induced coronary artery
      dissection in individuals who have received beta radiation treatment and
      to propose a new intravascular ultrasound (IVUS) dissection score to
      facilitate the comparison of dissection through time. DESIGN:
      Retrospective study. SETTING: Tertiary referral centre. PATIENTS: 31
      patients with stable angina pectoris, enrolled in the beta energy
      restenosis trial (BERT-1.5), were included. After excluding those who
      underwent stent implantation, the evaluable population was 22 patients.
      INTERVENTIONS: Balloon angioplasty and intracoronary radiation followed by
      quantitative coronary angiography (QCA) and IVUS. Repeat QCA and IVUS were
      performed at six month follow up. MAIN OUTCOME MEASURES: QCA and IVUS
      evidence of healing of dissection. Dissection classification for
      angiography was by the National Heart Lung Blood Institute scale. IVUS
      proven dissection was defined as partial or complete. The following IVUS
      defined characteristics of dissection were described in the affected
      coronary segments: length, depth, arc circumference, presence of flap, and
      dissection score. Dissection was defined as healed when all features of
      dissection had resolved. The calculated dose of radiation received by the
      dissected area in those with healed versus non-healed dissection was also
      compared. RESULTS: Angiography (type A = 5, B = 7, C = 4) and IVUS proven
      (partial = 12, complete = 4) dissections were seen in 16 patients
      following intervention. At six month follow up, six and eight unhealed
      dissections were seen by angiography (A = 2, B = 4) and IVUS (partial = 7,
      complete = 1), respectively. The mean IVUS dissection score was 5.2 (range
      3-8) following the procedure, and 4.6 (range 3-7) at follow up. No
      correlation was found between the dose prescribed in the treated area and
      the presence of unhealed dissection. No change in anginal status was seen
      despite the presence of unhealed dissection. CONCLUSION: beta radiation
      appears to alter the normal healing process, resulting in unhealed
      dissection in certain individuals. In view of the delayed and abnormal
      healing observed, long term follow up is indicated given the possible late
      adverse effects of radiation. Although in this cohort no increase in
      cardiac events following coronary dissections was seen, larger populations
      are needed to confirm this phenomenon. Stenting of all coronary
      dissections may be warranted in patients scheduled for brachytherapy after
      balloon angioplasty.</description>
    </item> <item>
      <title>Geographic miss: a cause of treatment failure in radio-oncology applied to intracoronary radiation therapy (Article)</title>
      <link>http://repub.eur.nl/res/pub/9373/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>BACKGROUND: A recognized limitation of endovascular beta-radiation therapy
      is the development of new stenosis at the edges of the irradiated area.
      The combination of injury and low-dose radiation may be the precursor of
      this phenomenon. We translated the radio-oncological concept of
      "geographic miss" to define cases in which the radiation source did not
      fully cover the injured area. The aims of the study were to determine the
      incidence and causes of geographic miss and evaluate the impact of this
      inadequate treatment on the outcome of patients treated with intracoronary
      beta-radiation. METHODS AND RESULTS: We analyzed 50 consecutive patients
      treated with beta-radiation after percutaneous coronary intervention. The
      prescribed dose ranged between 12 and 20 Gy at 2 mm from the source axis.
      By means of quantitative coronary angiography, the irradiated segment
      (IRS) and both edges were studied before and after intervention and at
      6-month follow-up. Edges that were injured during the procedure
      constituted the geographic miss edges. Twenty-two edges were injured
      during the intervention, mainly because of procedural complications that
      extended the treatment beyond the margins of the IRS. Late loss was
      significantly higher in geographic miss edges than in IRSs and uninjured
      edges (0.84+/-0.6 versus 0.15+/-0.4 and 0.09+/-0.4 mm, respectively;
      P&lt;0.0001). Similarly, restenosis rate was significantly higher in the
      injured edges (10% within IRS, 40.9% in geographic miss edges, and 1.9% in
      uninjured edges; P&lt;0.001). CONCLUSIONS: These data support the hypothesis
      that the combination of injury and low-dose beta-radiation induces
      deleterious outcome.</description>
    </item> <item>
      <title>Residual plaque burden, delivered dose, and tissue composition predict 6-month outcome after balloon angioplasty and beta-radiation therapy (Article)</title>
      <link>http://repub.eur.nl/res/pub/9374/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>BACKGROUND: Inhomogeneity of dose distribution and anatomic aspects of the
      atherosclerotic plaque may influence the outcome of irradiated lesions
      after balloon angioplasty (BA). We evaluated the influence of delivered
      dose and morphological characteristics of coronary stenoses treated with
      beta-radiation after BA. METHODS AND RESULTS: Eighteen consecutive
      patients treated according to the Beta Energy Restenosis Trial 1.5 were
      included in the study. The site of angioplasty was irradiated with the use
      of a beta-emitting (90)Sr/(90)Y source. With the side branches used as
      anatomic landmarks, the irradiated area was identified and volumetric
      assessment was performed by 3D intracoronary ultrasound imaging after
      treatment and at 6 months. The type of tissue, the presence of dissection,
      and the vessel volumes were assessed every 2 mm within the irradiated
      area. The minimal dose absorbed by 90% of the adventitial volume
      (D(v90)Adv) was calculated in each 2-mm segment. Diffuse calcified
      subsegments and those containing side branches were excluded. Two hundred
      six coronary subsegments were studied. Of those, 55 were defined as soft,
      129 as hard, and 22 as normal/intimal thickening. Plaque volume showed
      less increase in hard segments as compared with soft and normal/intimal
      thickening segments (P&lt;0.0001). D(v90)Adv was associated with plaque
      volume at follow-up after a polynomial equation with linear and nonlinear
      components (r = 0.71; P = 0.0001). The multivariate regression analysis
      identified the independent predictors of the plaque volume at follow-up:
      plaque volume after treatment, D(v90)Adv, and type of plaque. CONCLUSIONS:
      Residual plaque burden, delivered dose, and tiss composition play a
      fundamental role in the volumetric outcome at 6-month follow-up after
      beta-radiation therapy and BA.</description>
    </item> <item>
      <title>Positive geometric vascular remodeling is seen after catheter-based radiation followed by conventional stent implantation but not after radioactive stent implantation (Article)</title>
      <link>http://repub.eur.nl/res/pub/9460/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>BACKGROUND: Recent reports demonstrate that intracoronary radiation
      affects not only neointimal formation but also vascular remodeling.
      Radioactive stents and catheter-based techniques deliver radiation in
      different ways, suggesting that different patterns of remodeling after
      each technique may be expected. METHODS AND RESULTS: We analyzed
      remodeling in 18 patients after conventional stent implantation, 16
      patients after low-activity radioactive stent implantation, 16 patients
      after higher activity radioactive stent implantation, and, finally, 17
      patients who underwent catheter-based radiation followed by conventional
      stent implantation. Intravascular ultrasound with 3D reconstruction was
      used after stent implantation and at the 6-month follow-up to assess
      remodeling within the stent margins and at its edges. Preprocedural
      characteristics were similar between groups. In-stent neointimal
      hyperplasia (NIH) was inhibited by high-activity radioactive stent
      implantation (NIH 9.0 mm(3)) and by catheter-based radiation followed by
      conventional stent implantation (NIH 6.9 mm(3)) compared with low-activity
      radioactive stent implantation (NIH 21.2 mm(3)) and conventional stent
      implantation (NIH 20.8 mm(3)) (P:=0.008). No difference in plaque or total
      vessel volume was seen behind the stent in the conventional, low-activity,
      or high-activity stent implantation groups. However, significant increases
      in plaque behind the stent (15%) and in total vessel volume (8%) were seen
      in the group that underwent catheter-based radiation followed by
      conventional stent implantation. All 4 groups demonstrated significant
      late lumen loss at the stent edges; however, edge restenosis was seen only
      in the group subjected to high-activity stent implantation and appeared to
      be due to an increase in plaque and, to a lesser degree, to negative
      remodeling. CONCLUSIONS: Distinct differences in the patterns of
      remodeling exist between conventional, radioactive, and catheter-based
      radiotherapy with stenting.</description>
    </item> <item>
      <title>Three-dimensional intravascular ultrasound assessment of noninjured edges of beta-irradiated coronary segments (Article)</title>
      <link>http://repub.eur.nl/res/pub/9470/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>BACKGROUND: The "edge effect," late lumen loss at the margins of the
      treated segment, has become an important issue in the field of coronary
      brachytherapy. The aim of the present study was to assess the edge effect
      in noninjured margins adjacent to the irradiated segments after
      catheter-based intracoronary beta-irradiation. METHODS AND RESULTS:
      Fifty-three vessels were assessed by means of 3-dimensional intravascular
      ultrasound after the procedure and at 6- to 8-month follow-up. Fourteen
      vessels (placebo group) did not receive radiation (sham source), whereas
      39 vessels were irradiated. In the irradiated group, 48 edges (5 mm in
      length) were identified as noninjured, whereas 18 noninjured edges were
      selected in the placebo group. We compared the volumetric intravascular
      ultrasound measurements of the noninjured edges of the irradiated vessels
      with the fully irradiated nonstented segments (IRS, n=27) (26-mm segments
      received the prescribed 100% isodose) and the noninjured edges of the
      vessels of the placebo patients. The lumen decreased (6 mm(3)) in the
      noninjured edges of the irradiated vessels at follow-up (P:=0. 001). We
      observed a similar increase in plaque volume in all segments: noninjured
      edges of the irradiated group (19.6%), noninjured edges of the placebo
      group (21.5%), and IRS (21.0%). The total vessel volume increased in the
      IRS in the 3 groups. No edge segment was subject to repeat
      revascularization. CONCLUSIONS: The edge effect occurs in the noninjured
      margins of radiation source train in both irradiated and placebo patients.
      Thus, low-dose radiation may not play an important role in this
      phenomenon, whereas nonmeasurable device injury may be considered a
      plausible alternative explanation.</description>
    </item> <item>
      <title>Single dose irradiation response of pig skin: a comparison of brachytherapy using a single, high dose rate iridium-192 stepping source with 200 kV X-rays (Article)</title>
      <link>http://repub.eur.nl/res/pub/9541/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>An experimental brachytherapy model has been developed to study acute and
          late normal tissue reactions as a tool to examine the effects of
          clinically relevant multifractionation schedules. Pig skin was used as a
          model since its morphology, structure, cell kinetics and radiation-induced
          responses are similar to human skin. Brachytherapy was performed using a
          microSelectron high dose rate (HDR) afterloading machine with a single
          stepping source and a custom-made template. In this study the acute
          epidermal reactions of erythema and moist desquamation and the late dermal
          reactions of dusky mauve erythema and necrosis were evaluated after single
          doses of irradiation over a follow-up period of 16 weeks. The major aims
          of this work were: (a) to compare the effects of iridium-192 (192Ir)
          irradiation with effects after X-irradiation; (b) to compare the skin
          reactions in Yorkshire and Large White pigs; and (c) to standardize the
          methodology. For 192Ir irradiation with 100% isodose at the skin surface,
          the 95% isodose was estimated at the basal membrane, while the 80% isodose
          covered the dermal fat layers. After HDR 192Ir irradiation of Yorkshire
          pig skin the ED50 values (95% isodose) for moderate/severe erythema and
          moist desquamation were 24.8 Gy and 31.9 Gy, respectively. The associated
          mean latent period (+/- SD) was 39 +/- 7 days for both skin reactions.
          Late skin responses of dusky mauve erythema and dermal necrosis were
          characterized by ED50 values (80% isodose) of 16.3 Gy and 19.5 Gy, with
          latent periods of 58 +/- 7 days and 76 +/- 12 days, respectively. After
          X-irradiation, the incidence of the various skin reactions and their
          latent periods were similar. Acute and late reactions were well separated
          in time. The occurrence of skin reactions and the incidence of effects
          were comparable in Yorkshire and Large White pigs for both X-irradiation
          and HDR 192Ir brachytherapy. This pig skin model is feasible for future
          studies on clinically relevant multifractionation schedules in a
          brachytherapy setting.</description>
    </item> <item>
      <title>Comparison of brachytherapy strategies based on dose-volume histograms derived from quantitative intravascular ultrasound. (Article)</title>
      <link>http://repub.eur.nl/res/pub/4929/</link>
      <pubDate>1999-04-01T00:00:00Z</pubDate>
      <description>PURPOSE: We present in this paper the comparison, by simulation, of different treatment strategies based either on beta- or gamma-sources, both with and without a centering device. Ionizing radiation to prevent restenosis is an emerging modality in interventional cardiology. Numerous clinical studies are presently being performed or planned, but there is variability in dose prescription, and both gamma- and beta-emitters are used, leading to a wide range of possible dose distributions over the arterial vessel wall. This paper discusses the potential merits of dose-volume histograms (DVH) based on three-dimensional (3-D) reconstruction of electrocardiogram (ECG)-gated intravascular ultrasound (IVUS) to compare brachytherapy treatment strategies. MATERIALS AND METHODS: DVH describe the cumulative distribution of dose over three specific volumes: (1) at the level of the luminal surface, a volume was defined with a thickness of 0.1 mm from the automatically detected contour of the highly echogenic blood-vessel interface; (2) at the level of the IVUS echogenic media-adventitia interface (external elastic lamina [EEL]), an adventitial volume was computed considering a 0.5-mm thickness from EEL; and (3) the volume encompassed between the luminal surface and the EEL (plaque + media). The IVUS data used were recorded in 23 of 31 patients during the Beta Energy Restenosis Trial (BERT) conducted in our institution. RESULTS: On average, the minimal dose in 90% of the adventitial volume was 37 +/- 16% of the prescribed dose; the minimal dose in 90% of the plaque + media volume was 58 +/- 24% and of the luminal surface volume was 67 +/- 31%. The minimal dose in the 10% most exposed luminal surface volume was 296 +/- 42%. Simulations of the use of a gamma-emitter and/or a radioactive source train centered in the lumen are reported, with a comparison of the homogeneity of the dose distribution.</description>
    </item> <item>
      <title>Late coronary occlusion after intracoronary brachytherapy (Article)</title>
      <link>http://repub.eur.nl/res/pub/9154/</link>
      <pubDate>1999-01-01T00:00:00Z</pubDate>
      <description>BACKGROUND: Intracoronary brachytherapy appears to be a promising
      technology to prevent restenosis. Presently, limited data are available
      regarding the late safety of this therapeutic modality. The aim of the
      study was to determine the incidence of late (&gt;1 month) thrombosis after
      PTCA and radiotherapy. METHODS AND RESULTS: From April 1997 to March 1999,
      we successfully treated 108 patients with PTCA followed by intracoronary
      beta-radiation. Ninety-one patients have completed at least 2 months of
      clinical follow-up. Of these patients, 6.6% (6 patients) presented with
      sudden thrombotic events confirmed by angiography 2 to 15 months after
      intervention (2 balloon angioplasty and 4 stent). Some factors
      (overlapping stents, unhealed dissection) may have triggered the
      thrombosis process, but the timing of the event is extremely unusual.
      Therefore, the effect of radiation on delaying the healing process and
      maintaining a thrombogenic coronary surface is proposed as the most
      plausible mechanism to explain such late events. CONCLUSIONS: Late and
      sudden thrombosis after PTCA followed by intracoronary radiotherapy is a
      new phenomenon in interventional cardiology.</description>
    </item> <item>
      <title>Geometric vascular remodeling after balloon angioplasty and beta-radiation therapy: A three-dimensional intravascular ultrasound study (Article)</title>
      <link>http://repub.eur.nl/res/pub/9161/</link>
      <pubDate>1999-01-01T00:00:00Z</pubDate>
      <description>BACKGROUND: Endovascular radiation appears to inhibit intimal thickening
      after overstretching balloon injury in animal models. The effect of
      brachytherapy on vascular remodeling is unknown. The aim of the study was
      to determine the evolution of coronary vessel dimensions after
      intracoronary irradiation after successful balloon angioplasty in humans.
      METHODS AND RESULTS: Twenty-one consecutive patients treated with balloon
      angioplasty and beta-radiation according to the Beta Energy Restenosis
      Trial-1.5 were included in the study. Volumetric assessment of the
      irradiated segment and both edges was performed after brachytherapy and at
      6-month follow-up. Intravascular ultrasound images were acquired by means
      of ECG-triggered pullback, and 3-D reconstruction was performed by
      automated edge detection, allowing the calculation of lumen, plaque, and
      external elastic membrane (EEM) volumes. In the irradiated segments, mean
      EEM and plaque volumes increased significantly (451+/-128 to 490.9+/-159
      mm(3) and 201.2+/-59 to 241.7+/-74 mm(3); P=0.01 and P=0.001,
      respectively), whereas luminal volume remained unchanged (250.8+/-91 to
      249.2+/-102 mm(3); P=NS). The edges demonstrated an increase in mean
      plaque volume (26.8+/-12 to 32. 6+/-10 mm(3), P=0.0001) and no net change
      in mean EEM volume (71. 4+/-24 to 70.9+/-24 mm(3), P=NS), resulting in a
      decrease in mean luminal volume (44.6+/-16 to 38.3+/-16 mm(3), P=0.01).
      CONCLUSIONS: A different pattern of remodeling is observed in coronary
      segments treated with beta-radiation after successful balloon angioplasty.
      In the irradiated segments, the adaptive increase of EEM volume appears to
      be the major contributor to the luminal volume at follow-up. Conversely,
      both edges showed an increase in plaque volume without a net change in EEM
      volume.</description>
    </item> <item>
      <title>Preserved endothelium-dependent vasodilation in coronary segments previously treated with balloon angioplasty and intracoronary irradiation (Article)</title>
      <link>http://repub.eur.nl/res/pub/9177/</link>
      <pubDate>1999-01-01T00:00:00Z</pubDate>
      <description>BACKGROUND: Abnormal endothelium-dependent coronary vasomotion has been
      reported after balloon angioplasty (BA), as well as after intracoronary
      radiation. However, the long-term effect on coronary vasomotion is not
      known. The aim of this study was to evaluate the long-term vasomotion of
      coronary segments treated with BA and brachytherapy. METHODS AND RESULTS:
      Patients with single de novo lesions treated either with BA followed by
      intracoronary beta-irradiation (according to the Beta Energy Restenosis
      Trial-1.5) or with BA alone were eligible. Of these groups, those patients
      in stable condition who returned for 6-month angiographic follow-up formed
      the study population (n=19, irradiated group and n=11, control group).
      Endothelium-dependent coronary vasomotion was assessed by selective
      infusion of serial doses of acetylcholine (ACh) proximally to the treated
      area. Mean luminal diameter was calculated by quantitative coronary
      angiography both in the treated area and in distal segments. Endothelial
      dysfunction was defined as a vasoconstriction after the maximal dose of
      ACh (10(-6) mol/L). Seventeen irradiated segments (89.5%) demonstrated
      normal endothelial function. In contrast, 10 distal nonirradiated segments
      (53%) and 5 control segments (45%) demonstrated endothelium-dependent
      vasoconstriction (-19+/-17% and -9.0+/-5%, respectively). Mean percentage
      of change in mean luminal diameter after ACh was significantly higher in
      irradiated segments (P=0.01). CONCLUSIONS: Endothelium-dependent
      vasomotion of coronary segments treated with BA followed by beta-radiation
      is restored in the majority of stable patients at 6-month follow-up. This
      functional response appeared to be better than those documented both in
      the distal segments and in segments treated with BA alone.</description>
    </item> <item>
      <title>beta-Particle-emitting radioactive stent implantation. A safety and feasibility study (Article)</title>
      <link>http://repub.eur.nl/res/pub/9179/</link>
      <pubDate>1999-01-01T00:00:00Z</pubDate>
      <description>BACKGROUND: This study represents the Heart Center Rotterdam's
      contribution to the Isostents for Restenosis Intervention Study, a
      nonrandomized multicenter trial evaluating the safety and feasibility of
      the radioactive Isostent in patients with single coronary artery disease.
      Restenosis after stent implantation is primarily caused by neointimal
      hyperplasia. In animal studies, beta-particle-emitting radioactive stents
      decrease neointimal hyperplasia by inhibiting smooth muscle cell
      proliferation. METHODS AND RESULTS: The radioisotope (32)P, a
      beta-particle emitter with a half-life of 14.3 days, was directly embedded
      into the Isostent. The calculated range of radioactivity was 0.75 to 1.5
      microCi. Quantitative coronary angiography measurements were performed
      before and after the procedure and at 6-month follow-up. A total of 31
      radioactive stents were used in 26 patients; 30 (97%) were successfully
      implanted, and 1 was embolized. Treated lesions were in the left anterior
      descending coronary artery (n=12), the right coronary artery (n=8), or the
      left circumflex coronary artery (n=6). Five patients received additional,
      nonradioactive stents. Treated lesion lengths were 13+/-4 mm, with a
      reference diameter of 2.93+/-0. 47 mm. Minimum lumen diameter increased
      from 0.87+/-0.28 mm preprocedure to 2.84+/-0.35 mm postprocedure. No
      in-hospital adverse cardiac events occurred. All patients received aspirin
      indefinitely and ticlopidine for 4 weeks. Twenty-three patients (88%)
      returned for 6-month angiographic follow-up; 17% of them had in-stent
      restenosis, and 13% had repeat revascularization. No restenosis was
      observed at the stent edges. Minimum lumen diameter at follow-up averaged
      1.85+/-0.69 mm, which resulted in a late loss of 0.99+/-0. 59 mm and a
      late loss index of 0.53+/-0.35. No other major cardiac events occurred
      during the 6-month follow-up. CONCLUSIONS: The use of radioactive stents
      with an activity of 0.75 to 1.5 microCi is safe and feasible.</description>
    </item> <item>
      <title>Betaalde liefde (Inaugural Lecture)</title>
      <link>http://repub.eur.nl/res/pub/7485/</link>
      <pubDate>1997-12-18T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Intracoronary Brachytherapy: The Death Knell of Restenosis or Just Another Episode of a Never-Ending Story? (Article)</title>
      <link>http://repub.eur.nl/res/pub/4983/</link>
      <pubDate>1997-01-01T00:00:00Z</pubDate>
      <description>Writing an editorial on a newly emerged mode of therapy is a dilemma: either one emphasizes the promises of this new modality of treatment at the risk of being perceived as a noncritical and naive editorialist, or the potential hazards and the inherent limitations of the novel treatment are highlighted with the possibility of the editorialist being perceived as a nommaginative killjoy.</description>
    </item> <item>
      <title>Honderd jaar radiologie in Nederland. V. Radiotherapie, toekomstige ontwikkelingen. (Article)</title>
      <link>http://repub.eur.nl/res/pub/3089/</link>
      <pubDate>1995-01-01T00:00:00Z</pubDate>
      <description></description>
    </item>
  </channel>
</rss>